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Kortikalt bentap i hender ved revmatoid artritt. 
Evaluering av digital X-ray radiogrammetry som mål for sykdomsaktivitet, 
responsvariabel ved behandling og prediktor for benødeleggelse.
Revmatoid artritt (RA) er en inflammatorisk sykdom som angriper ledd. Sykdommen har varierende 
forløp, og det er viktig å velge ut pasienter med dårlig prognose tidlig i sykdomsforløpet. Det finnes i 
dag legemidler kan bremse benødeleggelse i ledd (erosjoner), og de mest brukte medikamentene 
hemmer tumor nekrose faktor-Į (anti-TNF terapi). Det eksisterer ingen enkel blodprøve eller test som 
kan forutsi prognose. Gullstandarden er å bedømme erosjoner på røntgenbilder av hender.  
Avkalkning av leddet, eller leddnær osteoporose, kan imidlertid sees før erosjoner, men kan ikke 
bedømmes kvantitativt ved å se på røntgenbilder.  
Formålet med denne avhandlingen var å vurdere nytten av en målemetode som måler leddnær 
osteoporose i hender for bedømming av sykdomsaktivitet og prognose ved RA.  
Det er brukt en databasert metode, digital X-ray radiogrammetry (DXR) som måler kortikal bentetthet 
(DXR-BMD) og kortikal ratio (DXR-MCI) fra røntgenbilder av hender.  
Hovedfunn
Artikkel 1 inkluderte 215 RA pasienter som ble fulgt i 2 år. Her ble DXR sammenlignet med den mest 
brukte metoden for bentetthetsmåling: Dual energy X-ray absorptiometry (DXA). Tap av ben målt ved 
DXR ble påvirket av sykdomsaktivitet, mens dette ikke kunne vises ved DXA. DXA tap ble bare 
funnet hos pasienter som hadde kort sykdomsvarighet.  
Artikkel 2 var en 10-års oppfølgingsstudie på 136 RA pasienter med sykdomsvarighet 4 år. De som 
tapte DXR-BMD etter ett år hadde betydelig større røntgenødeleggelse både etter 5 og 10 år, selv etter 
justering for de mest brukte prediktorer for fremtidig leddødeleggelse slik som positiv revmafaktor i 
blod (anti-CCP), høy inflammasjon (målt med CRP) og erosjoner på røntgenbilder i tidlig 
sykdomsfase. 
Artikkel 3 var en 2 års dobbeltblind, randomisert studie på 768 pasienter med RA hvor effekten av 
behandling med anti-TNF terapi ble vurdert. Pasientene var inndelt i 3 behandlingsarmer: 
Methotrexate (MTX), anti-TNF terapi (adalimumab) eller en kombinasjon av disse. 
Kombinasjonsgruppen mistet minst ben målt med DXR, de som bare fikk anti-TNF terapi mistet mer 
mens MTX gruppen mistet mest.  
Artikkel 4 vurderte presisjonen av DXR. Studien viste at DXR hadde en svært god presisjon (CV %) 
på 0.14-0.46 % avhengig av røntgenmaskin. 
Konklusjon
DXR er en enkel og nøyaktig målemetode for å påvise kortikalt bentap i hender. DXR påvirkes av 
sykdomsaktivitet, behandling med anti-TNF terapi og kan prediktere senere leddødeleggelse.  
DXR synes å ha de forutsetninger som skal til for å kunne bli et hjelpemiddel i vurdering av 
behandling og prognose hos den enkelte leddgiktpasient. 
Cand.med. Mari Hoff 
Institutt for nevromedisin 
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SUMMARY IN ENGLISH 
Cortical hand bone loss in rheumatoid arthritis
Evaluating digital X-ray radiogrammetry as outcome measure of disease activity, 
response variable to treatment and predictor of bone damage 
Background and objective 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease characterised by 
destruction of joints. The outcome in RA is heterogeneous, and it is important to select the 
patients with high risk for serious bone damage in the joints early in the disease course. New 
treatment with biologic agents has the ability to halter this damage, the most used agents 
block anti-tumour necrosis factor alpha (anti-TNF therapy). There exist no simple tests that 
can predict the progression in the individual patient. The gold standard is to evaluate the joint 
destruction (erosions) on radiographs of the hands. Periarticular osteoporosis is a sign that 
may appear before the erosions, however can not be quantified based on the visual 
impressions seen on radiographs. 
The objective of this doctoral thesis was to evaluate the value of a new method of measuring 
periarticular osteoporosis to assess disease activity and prognosis in RA patients.
Methods
Periarticular osteoporosis was measured by digital X-ray radiogrammetry (DXR) which 
measures cortical bone mineral density (BMD) and cortical ratio (MCI) from radiographs of 
the hands. The computer calculates DXR in a defined area in the metacarpal bones 2-4.  
This thesis consists of four papers: Two longitudinal observational studies (Paper 1 and 2), 
one blinded randomised study (Paper 3) and one study evaluating the precision of the DXR 
method (Paper 4). 
Results
Paper 1 included 215 patients followed for two years. In this study DXR was compared to the 
gold standard for measuring BMD: Dual energy X-ray absorptiometry (DXA). Loss of 
cortical bone measured by DXR was influenced by disease activity, while DXA-BMD loss 
was not. DXA-BMD loss was only found in a subgroup with short disease duration (<3years).
Paper 2 was a 10-year observational study in 136 RA patients with disease duration 4 years. 
The patients who lost DXR the first year of follow-up had a greater joint damage on 
radiographs both after 5 and 10 years, even when corrected for the present most used 
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predictors: Positive rheumatoid factor (anti-CCP), high inflammation measured by C-reactive 
protein and presence of erosions on radiographs. 
Paper 3 was a 2-year double blind, randomised study of 768 patients with RA evaluating the 
effect of anti-TNF therapy on hand bone. The patients were divided in three treatment groups: 
Methotrexate (MTX), anti-TNF therapy (adalimumab) or a combination of these. The 
combination group lost less hand bone, the anti-TNF therapy monotherapy group lost more 
and the MTX group lost most hand bone. The order of hand bone loss across the three 
treatment groups was similar to the order of radiographic progression. 
Paper 4 evaluated the precision of DXR. A satisfying precision of 0.14-0.46 was found 
dependent of the radiographic equipment.    
Conclusions
Hand bone loss measured by DXR is a feasible and precise method. It is influenced by disease 
activity, treatment with anti-TNF therapy and can predict subsequent radiographic bone 
damage. This thesis support that DXR has the potential to be a useful tool evaluating the 
disease severity in the individual RA patients. 
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1. INTRODUCTION 
1.1 Background 
1.1.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease characterised by 
synovitis and destruction of cartilage and bone in joints, especially the small joints of the 
hands and feet (1;2). The prevalence is about 0.5-1.0 % (3;4) with an annual incidence of 25-
50/100.000 (4;5). This makes RA to one of the most frequent inflammatory rheumatic 
diseases. The morbidity is not only limited to the joint manifestations. Other organs which can 
be affected by the disease is skeleton, lung, kidney, vascular system, bone marrow and eyes 
(6). In RA mortality has also been found to be increased (6). For the individual patient the 
course of the disease can be devastating and for the health care system the economic burden 
may be considerable. 
The aetiology is unknown, but according to our current understanding RA is an 
autoimmune inflammatory disease. In the majority of RA patients autoantibodies are 
detectable in serum (7). Autoantibodies against cyclic citrullinated peptide (anti-CCP) and 
immunoglobulin-M rheumatoid factor (IgM RF) are shown to be of diagnostic value and to 
predict poor outcome in terms of radiographic progression, physical function and mortality (7-
9). In addition to autoantibodies (7) both genes (10) and environmental factors are considered 
to be central in the pathogenesis. The main genetic risk of RA comes from specific alleles at 
the HLA-DRB1 locus encoding the shared epitope (11;12), as well as the protein tyrosine 
phosphate gene N22 (PTPN 22) which both has been found to influence the course of the 
disease (13). Cigarette smoking is the major known environmental risk factor for RA (14), 
and the fact that RA is 2-4 times more common in females suggests an influence of sex-
hormones (1;15).  
The most frequent used treatment for RA is still disease modifying anti-rheumatic 
treatment (DMARDs), especially methotrexate (MTX). However, during the last decade 
biologic treatment targeting specific cytokines or molecules involved in the RA disease 
process has become available for use in clinical practice (9). The current commercially 
available biologic treatment consists of anti-TNF therapy (e.g. antibodies against tumour 
necrosis factor-alpha (TNF-Į) or soluble TNF-Į receptor antagonist); antibodies against CD-
20 antigen expressed on B-lymphocytes; antibodies against interleukin (IL) 1 and 6; and T-
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cell modulators. This new paradigm in treatment has improved the prognosis and outcome for 
RA patients (9). 
1.1.2 Bone involvement in rheumatoid arthritis 
While the disability in early RA is driven by inflammation, the destruction of bone is the main 
reason for disability in established RA (2;9;16). Bone involvement in RA presents as erosions, 
generalized osteoporosis and periarticular (juxtaarticular) osteoporosis (Figure 1). Erosions 
and periarticular bone loss are both characteristic features on radiographs in RA and are 
included in the 1987 American College of Rheumatology (ACR) revised criteria of RA (17). 
Erosions on radiographs are specific for RA. However, the disadvantage is that joint damage 
may not appear on the radiographs early in the disease process. Periarticular osteoporosis is a 
typical radiographic finding in RA and may occur before the erosions are visible (18;19). It is 
considered as a hallmark of RA and may distinguish RA from other rheumatic diseases 
(20;21). However, hand bone loss can not be quantified on radiographs and it is estimated that 
bone loss less than 20-40 % can not be detected on plain radiographs (22;23). Quantitative 
hand bone measurements which capture periarticular osteoporosis have therefore been 
proposed as outcome measures in early RA (21;24). 
An increased risk of general osteoporosis in RA is well known, and it is considered as 
an important extra-articular complication (25;26).  Prevalence data on bone mineral density 
(BMD) reduction in RA has shown a 2-fold increase in osteoporosis for both women (26) and 
men (27). An increased risk for both vertebral (28) and hip fractures (29;30) has also been 
reported. In addition to the risk factors for primary osteoporosis as age, gender, menopause 
and peak bone mass, additional risk factor for osteoporosis in RA are immobilisation, 
medication and inflammation (27). 
Use of corticosteroids has been considered as a major risk factor for osteoporosis, but 
MTX has also been related to low bone density (31). Corticosteroids has been shown to 
influence the calcium metabolism by reducing uptake from the intestines and augment the 
urinary excretion; to stimulate the bone resorptive cells (osteoclasts); to influence the function 
and lifespan of bone building cells (osteoblast); and to increase apoptosis of the cells 
imbedded in the bone (osteocyte, which is a mature osteoblast that no longer secretes bone 
matrix, but maintains bone metabolism) (32;33). Concerning MTX, a clinical syndrome called 
“MTX osteopathy” has been described (31). This syndrome is characterized by stress 
fractures, diffuse bone pain and osteoporosis in children treated for malignancies. In animal 
studies high dose MTX has been shown to induce apoptosis in osteocytes and suppress 
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proliferation of the cells in the growth plate (chondrocytes) as well as the osteoblasts and 
preosteoblasts (34). However, low-dose MTX (5-20 mg/week) both in cross-sectional (35;36) 
and longitudinal studies (37) has not indicated any negative effect on bone in adults. 
Figure 1. Bone involvement in rheumatoid arthritis.
Generalised Fractures
Osteoporosis
Periarticular
1.1.3 Mechanism for bone involvement in rheumatoid arthritis 
As mentioned, bone involvement in RA presents as erosions, generalized osteoporosis and 
periarticular osteoporosis. The osteoclast is the main cell for bone resorption and an increase 
in the osteoclast activity causes osteoporosis (38), and osteoclasts have also been identified as 
responsible for bone resorption in RA (39). Substantial evidence from animal studies has 
shown that osteoclasts are essential for the development of joint destruction in arthritis 
(40;41). In one animal study transgenic mice that expressed human TNF-Į and who 
developed a severe destructive arthritis were crossed with mice lacking osteoclasts. The 
resulting mutant mice developed arthritis, but were fully protected against bone destruction 
(40). Further, suppression the osteoclast by the potent bisphosphonate zoledronic acid, has 
indicated a reduction of erosions in animal studies (41-43). 
Osteoclasts are multinucleated cells of hemapoetic origin from the monocytic cell line. 
Monocytes are entering the inflamed joint space and receive signals for further differentiation 
into osteoclasts (44). Expression of cathepsin K and tartrate-resistant acid phosphatase 
(TRAP) are early differentiation markers for osteoclastogenesis indicating formation of 
osteoclast precursors, while expression of calcitonin receptor is a late differentiation marker 
only found at sites of  bone resorption or inflammation (45).  
The activation and development of osteoclasts depends on stimulation from receptor 
activator of nuclear factor-ț ligand (RANKL). RANKL is also known as osteoclast 
Inflammation
Joint
destructionErosionsosteoclast 
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differentiation factor (ODF) (46), osteoprotegerin ligand (OPGL) and TNF-related activation-
induced cytokine (TRANCE) (45). The American Society for Bone and Mineral Research 
(ASBMR) president’s committee on nomenclature has recommended that this factor should 
be designated as “RANKL” (45). 
RANKL is a member of the TNF ligand superfamily of cytokines and bind to the 
receptor activator of nuclear factor-ț (RANK) (45). The interaction between this receptor-
ligand pair is essential for osteoclastogenesis (47). Mice with a serum transfer model of 
arthritis that were lacking RANKL were protected against bone destruction due to no 
stimulation of the osteoclasts (48). RANKL are predominantly expressed by activated T-
lymphocytes and synovial fibroblast-like cells (45). Osteoprotegerin (OPG) is a naturally 
occurring decoy receptor for RANKL. It prevents the binding of RANKL to RANK and 
inhibit the biological activity of RANKL. The ratio of RANKL/OPG is determining the 
degree of osteoclast mediated bone resorption (45;49). 
The expression of RANKL is stimulated by pro-inflammatory cytokines as TNF-Į,
IL-1, IL-6, IL-16, IL-17 and macrophage colony-stimulating factor (M-CSF) (49). It has also 
been suggested that TNF-Į have the ability to bind directly to osteoclasts precursor through 
TNF-Į receptor and stimulate the osteoclast formation (44;50). This gives TNF-Į a dual effect 
on osteoclast formation. 
The important role of the osteoclast in the development of erosions in RA has also 
recently been confirmed in human studies (51;52). The bisphosphonate zoledronic acid and 
the new antibody against RANKL, denosumab, are both potent suppressors of the osteoclast, 
and have been found to reduce the development of erosions in RA (51;52). Neither of the 
drugs did influence on disease activity. 
Recently, a growing interest for the osteoblast has developed in inflammatory arthritis. 
An increased bone resorption should normally be coupled to an increased bone formation by 
the osteoblast, but this is not the case in RA. Studies suggest that the inflammation may 
suppress the bone formation activity of the osteoblast. The osteoblast is activated by the Wnt 
(wingless protein) pathway which also leads to an induction of OPG and thus reduces the 
activity of the osteoclast (53;54). TNF-Į seems to induce Dickkopf 1 (DKK1) which inhibit 
Wnt. This further leads to a down-regulation of both the osteoblast and OPG, resulting in an 
inhibition of the bone formation. In this manner RA inflammation also seems to inhibit the 
osteoblast (53) which gives an additive negative effect of inflammation on bone. 
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1.1.4 Measurements of bone density 
Bone strength is dependent of many factors such as BMD (55), bone architecture (56), bone 
quality and bone geometry (57). Several devices have been developed for quantitative 
assessments of BMD (58), including quantitative ultrasound (US) (59), quantitative computer 
tomography (qCT) (60), dual energy X-ray absorptiometry (DXA) (61) and radiogrammetry 
(62).
Ultrasound measures velocity (speed of sound, SOS) and frequency-dependent 
attenuation (broadband ultrasound attenuation, BUA). The major advantage for US is that it 
does not involve use of ionizing radiation. Further SOS and BUA are supposed to provide 
information about bone structure in addition to bone density (59;63). So far US has mainly 
been used for heel and finger assessment, but a method that can be used on femoral bone has 
recently been developed (64;65). However, ultrasound is lacking a validated reference system 
for use in the clinic and the precision is highly operator dependent (66). For hand phalanx US 
the interobserver reproducibility expressed as coefficient of variance (CV %) has been 
reported to be 0.9-2.8 % for SOS and 0.7-1.4 % for BUA (67). 
Quantitative computer tomography (qCT) has the ability to determine the volumetric 
density three-dimensionally (g/cm3) and it can distinguish between cortical and trabecular 
bone. Disadvantages for this method are the high radiation dose and the high cost. 
Furthermore, the precision is poorer than for DXA (58;60). The CV % for qCT in the 
ultradistal radius was found to be 1.18 % for total bone, 1.29 % for BMD trabecular bone and 
1.67 % for cortical bone (68).
Dual energy X-ray absorptiometry (DXA) is considered as the gold standard for 
detection and management of osteoporosis (55;69). The main sites for measuring DXA is hip 
and spine, however every part of the skeleton can theoretically be measured by DXA. In the 
beginning of the 1990s a method for measuring DXA in hands was developed in a machine 
originally designed to measure DXA in hip and spine. The hand was positioned on a built-up 
plate consisting of sheets of perspex and aluminium (70). This method has been further 
developed, and software to measure DXA-BMD hand is now commercially available. In 
addition to measure whole hand, this software also have the possibility to measure regions of 
interest around the joints by a manual procedure (71). The bone density measured by DXA is 
both given as bone mineral content (BMC) and BMD. BMD is dependent on the area. In RA 
patients with severe deformities having difficulties to stretch their hand flat, it has been shown 
that the precision for BMD is dependent of the position of the hand while the precision of the 
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BMC is not (70). However, in most studies the precision is found to be better for DXA-BMD 
(coefficient of variation, CV % = 0.8-3.2 %) than for DXA-BMC (CV %=1.4-3.3 %), which 
has contributed to the selection of DXA-BMD as the most widely used method (24;72) (Table 
3).
In this study the main focus was to investigate cortical BMD in hands with a 
modernised version of the radiogrammetry method called digital X-ray radiogrammetry 
(DXR). This DXR method is a development of the classical radiogrammetry proposed by 
Barnett and Nordin in 1960 (73). Radiogrammetry was originally developed to detect 
generalised osteoporosis. On plain radiographs geometrical measures were used to calculate 
cortical ratio defined as the ratio of cortical bone divided by total bone. The method was used 
e.g. in the metacarpals, the ulnae, the radius, the femur and the spine (73). The major 
limitation of the manual method was the poor precision, mainly due to the indistinct endosteal 
margin (74). Measurements of metacarpal cortical index (MCI) gave an intra-observer error 
(CV %) up to 8-10 % (75). With the introduction of DXA the use of radiogrammetry became 
limited. The digitised version of radiogrammetry, DXR, has improved the precision and the 
feasibility. The first version (Pronosco X-posure version 1.0) was measuring cortical 
thickness in the second to fourth metacarpals as well as distal ulna and radius on conventional 
radiographs (76), but the method has been further developed to only include the second to 
fourth metacarpals (version 2.0) (77). DXR was approved by the US Food and Drug 
Administration in 1999 as a clinical method for estimating BMD substantially equivalent to 
DXA (76). More technical details on both DXA and DXR are given in chapter 2.2.2. 
1.1.5 Radiographs as outcome measure to detect bone damage in 
rheumatoid arthritis 
Radiographs are the most frequent used imaging methods to assess joint damage in RA. 
Different scoring methods to obtain joint damage have been developed, e.g. the Steinbrocker 
score, the Larsen score and the Sharp score (78;79). The Steinbrocker method was developed 
in 1949 and gave a global assessment of the patient (80). The grade (range I-IV) was 
determined by the worst change in any joint and was therefore biased toward the most 
severely affected joint. This method has therefore been replaced by the works of Larsen and 
Sharp which give a continuous scale of more than 100 units (78). 
The Larsen score was developed in 1974 and gives an overall score from 0-5 for both 
erosions and joint space narrowing (JSN) (81). This method has been modified several times. 
The most frequently used modification is from 1995 and includes 4 proximal interphalangeal 
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joints (PIP) and 4 metacarpophalangeal joint (MCP) from each hand, 4 regions from each 
wrist and 4 metatarsophalangeal joints (MTP) from each foot (82).  
In 1971 Sharp developed his method, which originally included only the hands and 
wrists (83). In this method JSN and erosions were scored separately, 29 regions for each hand 
and wrist were scored for presence of erosions and 27 regions in each hand and wrist for JSN. 
Several modifications of this method have been proposed (84-86), also including the feet (87-
89). In this thesis, two different modification of the Sharp method was applied; see also 
chapter 2.2.3 “Radiographic analyses” and Table 5. In Paper II the modification by van der 
Heijde (vdH Sharp score) was used which includes 16 regions for erosions and 15 regions of 
JSN in each hand and wrist as well as 6 joints for both erosions and JSN in each foot (87;89). 
In Paper III the applied modification of the Sharp method included 17 regions for erosions 
and 16 regions for JSN of each hand and wrist and 6 regions for erosions and 5 joints for JSN 
in each foot (88). No consensus exists on which modification of the Sharp score that should 
be applied (79).
1.1.6 Rheumatoid Arthritis and periarticular osteoporosis  
As mentioned in chapter 1.1.2 periarticular osteoporosis is a typical early radiographic finding 
in RA and may occur on radiographs before the erosions are visible (18;19). 
 Studies support the fact that hand bone loss measured by DXA and DXR takes place 
in early RA (20;21;24), even in the undifferentiated stage of the RA disease process (20;21). 
Patients with RA have significantly lower DXA-BMD hand compared to healthy controls (71) 
and patients suffering from psoriatic arthritis (90). In longitudinal studies, RA patients has 
been found to lose more hand BMD both compared to patients with other rheumatic diseases 
(20;21;72) and healthy controls (91) (Table 1). 
1.1.6.1 Periarticular versus generalised osteoporosis  
The small joints in hands and feet are the most frequently involved joints in the inflammatory 
disease process in RA (17). Thus, bone density measures of the hand are most frequent used 
for assessment of periarticular osteoporosis in RA whereas bone density measures at e.g. 
spine and hip are measurement sites for generalised osteoporosis. Studies indicate that hand 
bone loss in early RA occur more rapidly than bone loss at hip and spine (21;92;93). 
Radiographic joint damage has been shown to be more strongly correlated with low hand 
DXR-BMD than DXA-BMD at hip and spine (77;94). These studies suggest that whereas the 
prolonged course of RA including immobility and the use of corticosteroids may be more 
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associated to generalized bone loss (26), the effect of inflammation may have a greater impact 
on hand bone loss. 
1.1.6.2 The magnitude of hand bone loss
Age related changes in DXR-BMD and DXR-MCI in healthy adults have to our knowledge 
only been examined in cross-sectional studies (95-98).  
Calculations from cross-sectional studies have revealed an annual rate of bone loss for 
both DXR-BMD ad DXR-MCI of 0.4 % to 0.9 % in healthy individuals (95-98). Hand bone 
loss observed in patients with RA or other inflammatory joint disorders is depicted in Table 1.  
Assessments of hand DXA-BMD and DXA-BMC have mainly been performed in RA 
patients (Table 1). One year change in BMC among 37 healthy individuals (28 women, 14 
postmenopausal) was found to be 0.9 % for men and -0.9 % for women (91). Patients with 
other rheumatic diseases than RA have been found to lose less DXA-BMD (21;72) and DXA-
BMC (72) than patients with RA (Table 1). No reference population regarding age related loss 
of hand DXA-BMD or DXA-BMC exists. 
The peak bone mass for DXA hip and spine has been reported to occur approximately 
around 35-40 years (99), while the peak bone mass for DXR-BMD has been reported to occur 
between age 40-49 years (96;97). 
1.1.6.3 Predictors of hand bone loss and the association to inflammation 
The understanding of hand bone loss as outcome measure in RA is limited both due to lack of 
data from longitudinal studies and the small number of patients included in previous studies 
(21;24;91).
Only few studies have examined associations between disease factors and hand bone 
loss in RA, but most of these studies have focused on early disease (21;24;91). The change in 
DXA-BMD hand has been found to be inversely correlated to baseline C-reactive protein 
(CRP) (21;91). However, in a 2-year longitudinal study a significant correlation (correlation 
coefficient, r=0.3) between CRP at baseline and change in DXA-BMC was seen only in 
patients with early RA defined as disease duration less than two years, but not in patients with 
longer disease duration (91). These findings were replicated in another longitudinal study 
(24), suggesting that whole hand DXA-BMD loss only takes place in the first two-three years 
of the RA disease process. This may limit the use of hand DXA-BMD as outcome measure in 
established disease (24;91). A study of patients with early arthritis followed for 12 months, 
found CRP and rheumatoid factor (RF) to be independent factors for DXA hand bone loss 
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Table 1. Longitudinal studies on hand bone mass measurement in patients with 
rheumatic diseases. Numbers in parenthesis. 
Diagnosis
Study 
duration
Disease
duration
Disease
activity 
DXR-
BMD % 
change
DXR-
MCI % 
change
DXA-
BMC % 
change
DXA-
BMD % 
change
Deodhar et 
al 1995 
(91)
RA (81) 
1 yr 
Healthy (37) 
<2 yr (42)/ 
>2 yr (39) 
CRP: 17 
HAQ: 1.4 
M (33): -3.3 
-5.3/ -2.2 
F (48): -1.5 
-2.1/ 0.1 
M (9): 0.9 
F (28): -0.9 
Daragon et 
al 2001 
(72)
RA (15)/ 
ORD (15) 
1yr
<0.5 yr Active 
arthritis -2.2/ -0.3 -2.6/ -0.4 
Deodhar et 
al 2003 
(24)
RA (29) 
5yr
<2 yr CRP: 44 
HAQ: 1.1 
1 yr: -5.5 
2 yr: -7.5 
3 yr: -9.8 
5 yr: -10.0 
Jensen et 
al 2004 * 
(20)
RA (51)/ 
ORD (21) 
2yr
2 yr CRP: 95 
ESR: 14 
-5.0/
 -2.0 
NS
Stewart et 
al 2004
(100)
RA (24) 
Erosive/
non-erosive
4yr
<1 yr CRP: 16 
ESR: 36 
DAS: 3.3 
HAQ: 1.1 
1 yr: 
-7.1/
-0.2
1 yr 
-8.1/
-1.0
1 yr
-5.4/ -1.0 
Haugeberg
et al 2005
(101)
RA (95) 
Prednisolone 
users/  
non-users
2yr
<2 yr CRP: 33 
HAQ: 1.3 
-3.6/
-7.1
Böttcher
et al 2005
(102)
RA (258) 
6yr
<1 yr CRP>25 
ESR>20 
1 yr:-10.7 
6 yr:-32.1 
1 yr:-14.3 
6 yr:-33.3 
Haugeberg
et al 2006
(21)
RA (13)/
ORD (19)/ 
non-
inflammatory
(42) 
1yr
<1 yr CRP: 5 
HAQ: 0.6 
-4.3/
-0.5/
-0.9
Böttcher
et al 2006
(23)
RA (313) 
3yr
0.5-44 yr NA -22.3 -23.3
*: median change, otherwise mean change 
DXR= Digital X-ray radiogrammetry; BMD= Bone mineral density; MCI= metacarpal cortical index; 
DXA= Dual energy X-ray absorptiometry; BMC= Bone mineral content; yr= years; RA= rheumatoid 
arthritis; ORD= other rheumatic diseases; yr= years; CRP= C-reactive protein; ESR= Erythrocyte 
sedimentation rate; HAQ= Health assessment questionnaire, range 0-3; DAS= disease activity score; 
NA= Not available; NS= non-significant; M= Male; F= Female; N= Number 
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(21). In another study baseline number of swollen joint, HAQ-score and RF was also shown 
to be associated with change in DXA-BMC (24).
Cross-sectional studies have also demonstrated that hand BMD is lower in RA patients 
with high disease activity both for DXR (68) and DXA (92). Inflammation of the joints is, 
however, not restricted to the early phase of the RA disease, but may be present during the 
entire disease course (103). Thus, hand bone loss could theoretically be used as an outcome 
measure also in longstanding established RA. 
1.1.6.4 Hand bone loss as response measure to treatment
The ability of inflammatory treatment to reduce hand bone loss in RA has been demonstrated 
in a 2-year double blind study comparing prednisolone 7.5 mg /day with placebo (101). The 
prednisolone group had less hand BMD-DXR loss at one and two years suggesting that the 
potent anti-inflammatory effect of prednisolone exceeded its negative effect on bone (101). 
This findings was confirmed in a very recent study published in 2008 where RA patients 
treated with high dose prednisolone or anti-TNF therapy had lower rate of hand bone loss than 
patients treated with conventional DMARDs (93). 
Suppressing the inflammation by anti-TNF therapy has been demonstrated to 
significantly reduce the progression of radiographic joint damage in RA patients (88;104-
108). It is suggested that anti-TNF therapy may prevent general bone loss (109-111). RA 
patients treated with anti-TNF therapy have been shown to have lower rate of bone loss at 
spine and hip than at hand (93;110), suggesting that the inflammation have a more 
pronounced effect on hands than on generalised bone. 
1.1.6.5 Hand bone loss measured by DXA-BMD and DXR-BMD 
Only a few studies have compared hand BMD measured by DXA-BMD and DXR-BMD in 
RA (20;112). In a cross sectional study DXR-BMD was significantly correlated to 
radiographic damage while the association to DXA-BMD was borderline (112). Further, 
disease duration was significantly correlated with DXR-BMD but not with DXA-BMD. A 2-
year longitudinal study of patients with early RA and unclassified polyarthritis, found that 
DXR-BMD was associated to disease activity and decreased significantly through the study, 
while no changes in DXA-BMD were observed (20). 
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1.1.6.6 Hand bone loss and radiographic damage 
As previously described, both periarticular osteoporosis and erosions are known as 
radiographic hallmarks of RA (17). Despite this fact, there is a lack of data on the relationship 
between hand bone loss and radiographic damage. Studies with conventional radiographs 
have supported the idea that bone loss precedes the development of erosions (18;19). The 
cross-sectional correlation between DXA-BMD and radiographic damage has previously been 
examined in three small studies. Two of these studies demonstrated a significant correlation 
(r) of 0.24 - 0.69, respectively (70;113), whereas no correlation between erosions and DXA 
was seen in the third study (90). Four longitudinal studies have been performed examining 
radiographic changes and DXA changes. Two studies revealed no significant correlation 
(24;72), while in a 2-year longitudinal study including 43 patients a significant correlation (r= 
-0.55) was found (114). A study published in 2007 reported that the number of RA patients 
with early disease loosing hand DXA-BMD defined by the smallest detectable change (SDC) 
at 24 weeks was significantly higher than the number of patients with an increase more than 
SDC in the vdH Sharp score at 48 weeks (115). They concluded that DXA-BMD was a more 
sensible method to detect bone damage in early RA patients than conventional hand 
radiographic scores.
For the DXR-method, several cross-sectional studies have found DXR-BMD to be 
lower in patients with high scores of radiographic joint damage than in patients with a low 
radiographic damage score(23;67;68;77;94;102;116;117). For assessment of radiographic 
joint damage different scoring methods has been applied including modifications of the Sharp 
method (23;67;102;116;117), modifications of the Larsen method (23;77;94;102;117), the 
Ratingen score (68) and the Steinbrocker score(67;77;102). In all these studies the correlation 
coefficient (r) between radiographic damage and DXR-BMD ranged from -0.42 to -0.66.
In one longitudinal pilot study including 24 patients the data indicated that DXR-BMD 
loss the first year of follow-up in early RA (<1 year disease duration at inclusion) could 
predict erosions at 4-year follow-up (100).   
1.1.7 Personal background
During my work as a clinician I had become aware of how important it was to identify RA 
patients with high risk for severe bone destruction early in the disease course to improve their 
outcome. The interplay between the immune system and the bone fascinated me: Why did 
some patients with high inflammation not get any joint damage, while others apparently 
having less inflammation got destructions very fast? For a long time periarticular osteoporosis 
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has been known as an early feature on radiographs in RA patients (18) and has been 
recognised as a hallmark of RA (17). However, the benefit of using measurement of 
periarticular osteoporosis in RA as an outcome measure, and how to use these measures in 
clinical practice, had not been thoroughly examined. Diakonhjemmet hospital had access to a 
Pronosco X-posure 2.0 machine for measuring DXR from conventional hand X-rays. Some 
preliminary interesting work using this machine had already been done by my main 
supervisor Glenn Haugeberg (101;118). When I got the possibility to do my thesis on this 
project I was happy to assess the value of cortical hand bone loss in RA by using DXR as 
outcome measure of bone involvement and as a predictor of joint damage. 
During the last few years, the knowledge in this field has increased substantially, but 
when this study started in 2005, only small longitudinal studies with few patients had been 
published assessing hand bone loss and its association with disease activity and the influence 
of anti-inflammatory treatment on hand bone. A few double blind randomised clinical trials 
had shown that anti-TNF therapy could halt erosions (88;104-106), and this fact was 
supported by other studies in 2006 (107;108). The effect of anti-TNF therapy on periarticular 
and generalised osteoporosis had not been examined. Further the role of the osteoclast in bone 
damage in RA was not fully understood (44;119) and the focus on the osteoblast (53;54) is so 
new that it is not even discussed in my papers. 
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1.2 General Aim and specific research questions 
1.2.1 General aim 
The general aim of this thesis was to examine the potential role of quantitative measurements 
of hand BMD as assessed by DXR as outcome measure and as predictor of radiographic 
progression in patients with RA. 
1.2.2 Specific research questions 
x Does hand bone loss have a value as a disease outcome measure in early and 
established RA (Paper I and III)? 
x Which markers of the inflammatory disease process and disease severity are 
associated with hand bone loss in RA (Paper I and III)? 
x Is cortical hand bone loss, assessed with DXR-BMD, an early marker of bone 
involvement in RA (Paper II)? 
x Does cortical hand bone loss in early RA predict subsequent radiographic joint 
damage (Paper II)? 
x What is the clinical value of DXR-BMD compared to other predictors of radiographic 
damage as e.g. presence of erosions, CRP, anti-CCP and RF IgM (Paper II)? 
x Does potent suppression of inflammation with anti-TNF therapy prevent DXR hand 
bone loss in RA (Paper III)? 
x Does hand bone loss in RA as assessed by DXR compared with scoring of 
radiographic joint damage support the hypothesis of a common cellular mechanism of 
bone erosions and bone loss (Paper II and III)? 
x The precision for DXR-BMD assessed with Pronosco X-posure has been found to be 
superior to DXA-BMD hand. What is the precision of the new direct DXR method 
(dxr-online) (Paper IV)? 
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2. MATERIAL AND METHODS 
2.1 Study design and study population 
This thesis consists of two longitudinal observational studies; one double blind randomised 
study and one cross-sectional study. The DXR-method, which calculates BMD from 
radiographs, allowed us to use data from previously conducted studies with radiographs 
available.
2.1.1 Oslo Rheumatoid Arthritis Register (Paper I) 
The cohort in Paper I includes 215 patients (45 males and 170 females) from the Oslo RA-
register. The Oslo RA-register was established during the period 1991-1994 by Kvien and 
colleagues (3). To be included in the RA registry the patients had to fulfil the RA criteria (17) 
and have a residential address in Oslo. Disease onset was recorded as the date when at least 
four out of seven classification criteria of RA was fulfilled (17). Patients with juvenile RA 
were not included in the cohort. The completeness of the register has been validated and was 
found to be 85 % for patients aged 20-79 years (3). The register is continuously updated with 
new cases and withdrawals due to death or new address outside Oslo. 
From this register Haugeberg and colleagues described 2 year changes in hip and spine 
BMD in 366 patients (120) (Figure 2). The inclusion criteria were: Diagnosis of RA, age 20-
70 years, and Caucasian. Clinical, laboratory and radiographic data were collected at baseline 
and after 2 years follow-up. During the observation period, patients were treated according to 
clinical judgement by their rheumatologist.
In the present study only patients with hand radiographs and measurement of DXA-
BMD hand at baseline and 2 year follow-up from both hands were included. We used the 
mean of both hands to avoid bias regarding dominant and non-dominant hand. This approach 
has also been shown to improve precision for BMD assessment (115). We excluded 151 
patients who missed at least one BMD measurement. 
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Figure 2. Flowchart of the OSLO rheumatoid arthritis registry. 
OSLO RA registry (Age 20 – 70 years)
N=913  
(Male 192/ female 721) 
636 willing to undergo 
clinical investigation 
Clinical examination  
+ BMD hip and spine 
N= 488 (Male: 94/ female: 394) 
512 willing to measure  
BMD hip and spine 
24 excluded (not Caucasian or >70 yr)
2-year follow-up 
N=366 (Male: 68/ female: 298) 
Study population 
N=215 (Male: 45/ female: 170) 
Failed to follow-up 25% 
N=122 (Male: 26/ female: 96) 
Patients with incomplete BMD 
measurements in hands excluded 
N=151 (Male: 23/ female: 128) 
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2.1.2 The EURIDISS study sample (Paper II) 
The RA patients in Paper II were recruited from the European Research on Incapacitating 
Disease and Social Support (EURIDISS) longitudinal observational study. The EURIDISS 
study was a European multi-centre study and the participating centres were Nancy in France, 
Groningen in the Netherlands and Oslo in Norway. The original intension was to study the 
effects of social network and social support on chronic diseases, and RA patients with disease 
duration four years or less were selected as a model for chronic disease. The Norwegian 
patients were mainly recruited from the Department of Rheumatology at Diakonhjemmet 
hospital in Oslo. Some patients were also recruited from the Department of Rheumatology at 
the Martina Hansen Hospital (121;122). 
Inclusion criteria were diagnosis of RA (17), disease duration four years or less and 
age 20-70 years. At baseline in 1992 the Norwegian patient sample comprised 238 RA 
patients with mean disease duration of 2.3 years. All living patients who participated in the 
baseline visit (n=203) were asked to participate in the 10-year follow-up examination, 
resulting in 149 completers (Figure 3). 
Clinical, laboratory and radiographic data were collected at baseline and at 1, 2, 5 and 
10 years. Sera from the baseline visit were stored at -70 degrees Celsius for later analysis of 
micro-CRP, anti-CCP and IgM RF (8). During the observation period, patients were treated 
according to clinical judgement by their rheumatologist.
Patients with hand radiographs at baseline, 1 year follow-up and either 5 or 10 year follow-up 
were included in the present analyses. The number of patients with baseline radiographs 
available for scoring were 163, and 15 of these were excluded due to missing radiographs 
both at 5 and 10 year. Of the remaining 148 patients, baseline radiographs from five patients 
could not be analysed for DXR-BMD because the radiographs were underexposed and seven 
patients were excluded at the one year follow-up (five radiographs were missing, one 
underexposed and one patient had surgical material in the metacarpal bone). Finally, 136 
patients were included in the analyses. The EURIDISS cohort has also been used to 
investigate other predictors of radiographic damage such as anti-CCP, IgM RF, erythrocyte 
sedimentation rate (ESR), (8), as well as the shared epitope and the PTPN22 gene (13). 
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Figure 3. Flowchart of the EURIDISS rheumatoid arthritis cohort. 
238 patients included 163 hand X-rays available 
BASELINE clinical examination/ 5 DXR-BMD could not be 
analyzed blood samples  
(underexposed) 
2.1.3 The PREMIER study sample (Paper III)
The PREMIER study included 799 patients from 133 investigational sites. The main objective 
was to compare the efficacy and safety of adalimumab plus MTX versus adalimumab 
monotherapy and MTX monotherapy. The radiographic and clinical data from this 2-year, 
multi-centre, double-blind, randomised controlled study has previously been described in 
detail (108). Inclusion criteria were disease duration less than 3 years and aggressive RA (8
swollen joint; 10 tender joints; ESR of 28 or CRP 1.5 mg/dl; erosions or RF positive). 
Patients who previously had been treated with MTX, cyclophosphamide, cyclosporine, 
azathioprin or more than two other DMARDS were excluded. The combination group 
received adalimumab 40 mg subcutaneously every other week plus weekly oral MTX (rapidly 
increased to 20 mg/week), and the monotherapy groups received either adalimumab 40 mg sc 
every other week plus placebo or weekly oral MTX plus placebo. Clinical, laboratory and 
radiographic data were collected at baseline and at 26, 52, and 104 weeks of follow-up (108). 
In this study our initial intension was to use DXR-BMD as primary outcome. 
However, many radiographs could not be analysed for BMD because of unknown image 
229 patients  
clinical examination/ 
blood samples  
1 year 
follow-up 
5 year 
follow-up 
10 year 
follow-up 
182 patients 
clinical examination/ 
blood samples  
149 patients 
clinical examination 
blood samples  
164 hand X-rays available 
2 DXR-BMD could not be 
analysed  
(1 underexposed and 1 
metal in metacarpi) 
150 hand X-rays available 
149 hand X-rays available 
9 patients  
lost for
follow-up 
136 patients 
with hand 
radiographs at 
baseline, 1-year 
follow-up and  
47 patients 
lost for 
follow-up 
5-year or 10-year 
follow-up  
33 patients 
lost for 
follow-up 
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resolution. The calculation of DXR-BMD is based volume per area and requires a known 
resolution. The DXR device does also calculate DXR-MCI defined as combined cortical 
thickness divided on total width. DXR-MCI is therefore a relative measure, less dependent of 
image resolution, and was used as the primary outcome measure. The correlation between 
DXR-BMD and DXR-MCI has been found to be substantial (r >0.90), both cross-sectionally 
(77) and longitudinally (123). Further definition and information about DXR is described in 
paragraph 2.2.2.1. 
Results for DXR-BMD were also presented. All images with unknown resolution were 
analyzed by assuming 254 dpi (the scanning resolution for the radiographs before scoring). 
Several of the radiographs were, however, clearly of another resolution, most likely because 
these radiographs had been printed in non-true size before scanning. Based on analyses from 
studies with a controlled resolution (123), a deviation from baseline width greater than 2 % 
was likely to indicate an incorrect value. By using this 2 % value as a cut-off, 23 % of the 
radiographs were excluded from further DXR-BMD analyses. For DXR-MCI 768 radiographs 
were analysed at baseline and 537 at 2-year (compared to 799 and 539 in the original 
PREMIER). For DXR-BMD the respective numbers were 765 and 369 (Figure 4). 
2.1.4 The precision study (Paper IV) 
The precision study was duplex. The first part consisted of an in-vitro study where hand 
DXR-BMD was measured on the same cadaver forearm phantom 31 times with repositioning 
of the phantom between each radiograph, tested on four different standard X-ray equipments. 
All digitised radiographs were sent to Sectra and analysed with their new modified version of
DXR the dxr-online software system (“dxr-online” is the brand name and written with lower 
case letters). 
The second part consisted of an in-vivo precision study where the participants were 
recruited from consecutive individuals visiting an osteoporosis out-patient clinic. They were 
selected according to their total hip BMD values, 20 with osteoporosis and 20 with normal 
values. Unfortunately, one radiograph could not be analysed for DXR-BMD. Thus, 19 
individuals with osteoporosis and 20 with normal DXA-BMD values were included. All 
participants underwent duplicate hand radiographs with reposition between each image. 
Because this study consisted of phantoms and healthy individuals, no demographic or clinical 
data were collected. 
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Figure 4. Flowchart of the PREMIER early rheumatoid arthritis cohort.  
Numbers of missing X-rays compared with the original PREMIER study are provided 
in parentheses.
PREMIER Study 
N=799
Baseline adalimumab 
plus MTX 
PREMIER: 268 
DXR-MCI: 261 (7) 
DXR-BMD: 260 (8) 
Baseline adalimumab 
PREMIER: 274 
DXR-MCI: 261 (13) 
DXR-BMD: 259 (15) 
Baseline MTX
PREMIER: 257 
DXR-MCI: 246 (11) 
DXR-BMD: 246 (11) 
104 weeks 
PREMIER: 167 
DXR-MCI: 167 (0) 
DXR-BMD: 115 (52) 
104 weeks 
PREMIER: 169 
DXR-MCI: 169 (0) 
DXR-BMD: 118 (51) 
Total 104 weeks  
follow-up 
PREMIER: 539 
DXR-MCI: 537 (2)
DXR-BMD: 369 (170)
104 weeks 
PREMIER: 203 
DXR-MCI: 201 (2) 
DXR-BMD: 136 (67) 
MTX= methotrexate; DXR= digital X-ray radiogrammetry; MCI= metacarpal cortical index; 
BMD= bone mass density. 
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2.2 Measures  
2.2.1 Demographics and clinical measures 
A broad spectre of variables was available from the different cohorts. Table 2 gives a 
summary of the different cohorts used in Paper I- III. Paper IV was a precision study of 
phantoms and healthy individuals and therefore no demographic or clinical data were 
included. I will emphasize that median values are stated in Table 1, Paper 1 and may therefore 
differ slightly from this Table. 
Table 2. Baseline values of demographic and clinical measurements in the different 
papers. Mean (SD) for continuous variables, percentage for counts.  
Domain Variables Paper I Paper II Paper III 
Age years 55.4 (11.1) 51.3 (12.1) 52.0 (13.6) 
Female, % 79 76 75
BMI, kg/m2 24.2 (3.7)
Smoke, % 31
Demographics
Menopause, % 65
RA disease duration, years 11.0 (8.5) 2.2 (1.2) 0.75 (0.8) 
Rheumatoid factor, % 48 48
Anti-CCP, % 62
HAQ, 0-3 0.9 (0.6) 1.5 (0.6) 
MHAQ, 1-4 1.5 (0.4) 
ESR, mm/hr 19.4 (14.7) 26.2 (20.9) 
DAS28 4.1 (1.4) 6.3 (0.9) 
CRP, mg/l 9.4 (12.2) 40.0 (4.1) 
Swollen joint count 21.5
Disease
process
Tender joint count 31.7
DXA-BMD hand, g/cm2 0.37 (0.07) 
DXR-BMD, g/cm2 0.51 (0.09) 0.55 (0.09) 0.57 (0.08) 
DXR-MCI 0.38 (0.09) 0.45 (0.09) 
Bone
involvement
Radiographic score 6.8 (12.2) 19.0 (20) 
Current DMARDs, % 
Previous DMARDs, % 83
54 32
Current steroids, % 38 26 35
Medication
Current anti-osteoporotic 
therapy, % 
23
RA= rheumatoid arthritis; Anti-CCP= anti-cyclic citrullinated peptide; CRP= C-reactive protein; 
HAQ= health assessment questionnaire; MHAQ= modified health assessment questionnaire; ESR= 
erythrocyte sedimentation rate; DAS28= disease activity score for 28 joints; DXA= dual X-ray 
absorptiometry; BMD= bone mineral density; DXR= digital X-ray radiogrammetry; MCI= metacarpal 
cortical index; DMARDs= disease modifying anti rheumatic drugs 
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2.2.2 Bone Density measurements 
2.2.2.1 Digital X-ray Radiogrammetry 
DXR-BMD and DXR-MCI was in Paper I and II measured from standard, conventional 
radiographs by the Pronosco X-posure system TM, version 2.0 (Sectra, Linköping, Sweden) 
(62) and in Paper III and IV DXR was analysed by Sectra. 
DXR is a computer version of the traditional technique of radiogrammetry (73). On 
standard hand radiographs the computer uses an active shape model (124) to recognize 
regions of interest around the narrowest part of the second, third and fourth metacarpal bone, 
(Figure 5). In each region cortical thickness, bone width and porosity is measured about 118 
times per cm, (Figure 6). 
Figure 5. Hand X-ray with regions of interest for DXR analyses.  
The boxes indicate the narrowest part of metacarpi 2-4  
(photograph printed with permission from Sectra). 
BMD is defined as: Bone mass divided by area.  
Bone mass is defined as: Bone density multiplied by 
cortical volume corrected for porosity.  
Density is defined by a constant (c).
In Pronosco X-posure system TM, version 2.0 c is 
determined such as DXR-BMD (measured in 562 
women) on average is equal to the mid-distal forearm 
region of the Hologic QDR-2000 device. In the new 
direct DXR (dxr-online) c is adjusted by the calibration for the used radiographic equipment 
such that a set of five phantoms with a great range in bone density achieve the same BMD as 
in Pronosco X-posure.
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Figure 6. Outline of principles for determination of the basic quantities for 
radiogrammetry (photograph printed with permission from Sectra). 
R= radius of total bone
r= radius of trabecular bone
T= cortical thickness
W= width 
Volume is cortical volume and given as volume per area (VPA). Assuming that the bone of 
interest is cylindrical the VPA is defined as: ʌ x (R2-r2)/ W,
where R is the outer radius, r inner radius and W is the width, (Figure 6). VPA is calculated 
for the three metacarpi as a weighted average VPAcomb = (VPA2 + VPA3 + 0.5 VPA4) / 2.5, 
where VPA 2, 3 and 4 refer to VPA in metacarpus 2-4, respectively. 
Porosity (p) is defined as the percent of cavities not occupied of mineral matter (Figure 7). 
Porosity for each of the bones is derived from the area percentage (ratio) of local intensity 
minima (holes) found in the cortical part of the bone relative to the entire cortical area.
The p is usually about 2 % (sometimes it can be a bit higher) and is corrected in the BMD 
estimate as 1-p.  The final BMD estimate is defined as: 
DXR-BMD= (density constant x volume x (1-porosity)) / area = c x VPAcomb x (1-p)
(62;76).
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Figure 7. Measurement of porosity
(photograph printed with permission from Sectra).
DXR-BMD requires a known resolution, because the equation 
for DXR-BMD is based on volume per area and a distance in a 
digitized radiograph cannot be measured when the resolution is 
unknown.
DXR-MCI is defined as the combined cortical thickness 
divided by the bone width and represents a relative bone 
measure which is less dependent of bone size and bone length 
than DXR-BMD (98;125). From Figure 6 the equation is: 
DXR-MCI = (2 x (R-r)) / (2 x R). 
The DXR method has improved the precision of MCI for diagnosing cortical bone loss 
(73;75;125).
Direct DXR (or “dxr-online”) is a further development of the Pronosco X-posure 
system and has the advantage of analysing digitised radiographs. The direct DXR is 
calculated from the same formula and uses the same algorithm as the original DXR, except 
from the previously mentioned minor differences concerning the calculation of c. Digitised 
radiographs, from either computed radiography (CR) using a phosphorous plate, or digital 
radiography (DR), are sent online or as CD and is analysed at Sectra (Sectra Linköping, 
Sweden). This method was used in Paper IV. 
2.2.2.2 Dual X-ray absorptiometry 
In Paper I, standardised DXA-BMD measurements for left and right hand, total hip and spine 
(L2-4) were performed. The DXA is considered as the “gold standard”, and the method is 
based on the known differences in absorption of high energy and low energy X-rays by bone 
and soft tissue. The relative attenuation of two different energy levels can be used to subtract 
the soft tissue component making it possible to calculate the mineral density of the bone. 
The same DXA equipment Lunar Expert (Madison, Wisconsin) was used both at 
baseline and follow-up for all measurements. This software offers a mode for hand 
measurements and do not need a built-up plate consisting of sheets of perspex and aluminium 
as in the first measurements of DXA hand (70). We have chosen to use DXA of the whole 
hand. Even though measures of bone loss around the joints shown larger values of bone loss 
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the method for measuring whole hand is more feasible and the precision is considerably better 
than for regions around the finger joints (Table 3) (71;72). 
All technical procedures were in accordance with the manufacturer's standardized 
procedures. (For hand: Mode: 1mA fast. Field: length: 23 cm height: 14.4 cm. Exposure 
factor: time (sec): 18.9, voltage (kVp): 134.0, Current (mA): 1.0). 
2.2.2.3 Precision 
Table 3 gives a review over selected published precision data for DXR and DXA. For DXR-
BMD most previous studies have used non-dominant hand (20;62;76;98;102), while for DXA 
measures there are no consistence and mean of both hands (21;71;114;115;126), right hand 
(70;72;91;127) and non-dominant hand (20;90) have all been used. Most of the precision data 
for DXR were performed on the Pronosco X-posure version 1.0 system that also included ulna 
and radius as well as metacarpi 2-4. Prior to this study (Paper IV) no precision data for direct 
DXR had been published. 
Table 3. Data from selected studies on precision (expressed as percentage coefficient of 
variation, CV %) for dual energy X-ray and digital X-ray radiogrammetry. 
All studies performed with reposition between measurements 
Pronosco 1.0: DXR calculated from 2-4 metacarpi, distal ulnae and distal radius 
Pronosco 2.0: DXR calculated from 2-4 metacarpi 
*n: one hand, n: r= right, l= left, nd= non-dominant, **= mean of both hands, r+l = right and left hands 
DXR= digital X-ray radiogrammetry; BMD= bone mineral density; MCI= metacarpal cortical index; 
DXA= dual energy X-ray absorptiometry; BMC= bone mineral content; CV= coefficient of variation; 
PreM= pre menopausal; PostM= post menopausal; RA= rheumatoid arthritis; NA= not available 
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Study Method Localisation DXR-
BMD
DXR-
MCI
DXA-
BMD
DXA-
BMC
Deodhar et al 1994 
(70)
8 healthy 
3 times 
Whole hand*r 2.3
Alenfeld et al  2000 
(71)
5 healthy 
5 times 
Whole hand** 
Joint
0.9
2.7-3.2
Daragon et al 2001 
(72)
15 healthy 
2 times 
Whole hand*r
Joint
1.35
1.6-4.5
3.3
Harrison et al 2002 
(90)
10 arthritis 
4 times 
Joint*nd 0.9-1.6
Berglin et al 2003 
(114)
16 healthy 
NA
Whole hand** 1.1
Haugeberg et al 
2007 (115) 
81 healthy 
2 times 
Whole hand** 
Hip
Spine
0.82
2.33
2.75
Murphy et al 2008 
(128)
7 patients 
14 hands 
3 times 
Joint r+l 0.89-
2.37
1.38-
3.26
Jørgensen et al 
2000 (76) 
40 healthy 
3 times 
20 preM 
20 postM 
Pronosco
1.0*nd
0.68
0.61
Rosholm et al 2001 
(62)
11 healthy 
13 osteopor. 
2 times 
Pronosco
1.0*nd
0.59
0.59
Hyldstrup et al 
2001 (98) 
24 healthy 
2 times 
Pronosco
1.0*nd
0.64
Böttcher et al 2005 
(102)
1radiograph 
10 times 
Pronosco
2.0
0.19 0.24
Böttcher et al 2005 
(129)
1 phantom 
10 times 
Conventional/
printouts
Pronosco
2.0
0.33-
0.49/
0.33-
1.50
0.50/
0.78-
1.28
Hoff et al 2008 
(126)
28 healthy 
37 RA 
2 times 
Pronosco
2.0**
0.28
0.47
0.31
0.55
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2.2.3 Radiographic analyses 
Technical conditions for the radiographs used in the different studies in this thesis (Paper I-
IV) are depicted in Table 4. 
Table 4. Technical conditions for radiographic analyses. 
X-ray 
equipment
Conventional/ film 
Computed radiography 
(CR)
Digital radiography 
(DR)
Film
focus
distance
(FFD, cm) 
Tube
voltage
(kV)
Exposure
dose
(mAs)
Paper
Siemens
Multix
Conventional/
AGFA Crurix film 
100 55 6 I, II 
Different
equipments*
Single emulsion/ 
mammography film 
100 50-55 8 III
Agfa ADC 
Compact plus 
CR 100 50 5 II, IV 
Fuji FCR 
Profect
CR 100 40 8 IV
Fuji FCR XG1 CR 100 50 5 IV
Sectra
MicroDose
DR ”built in” 35 10 IV
cm= centimetre; kV= kilo volt; mAs= milliAmpere second 
*The PREMIER study was performed in 133 investigational sites on different radiographic 
equipments and tube voltage in accordance to this, but with a defined film, FFD, and exposure dose. 
In Paper II the van der Heijde modification of the Sharp score was performed (87;89), while 
in Paper III another modification of the Sharp method for detecting radiographic damage was 
used (84;88;108). Table 5 summaries the differences between the two scoring methods. 
Table 5. The differences between the two modifications of Sharp score. 
Erosions Joint space 
narrowing 
Max score 
vdH Sharp score
Hands/ wrists 
Numbers of joints (score) 16 (0-5) 15 (0-4) 280
Feet
Numbers of joints (score) 6 (0-10) 6 (0-4) 168
Total 448
Mod Sharp score
Hands/ wrists 
Numbers of joints (score) 17 (0-5) 16 (0-4) 298
Feet
Numbers of joints (score) 6 (0-5) 5 (0-4) 100
Total 398
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2.3 Statistical analyses 
The statistical analyses were carried out using the Statistical Package for the Social Sciences 
for Windows (SPSS Inc. Chicago, Il, USA), version 13 for Paper I and version 14 for Paper 
II-IV. In addition Excel (Microsoft Office) was used for precision calculations in Paper IV. 
Two tailed p-values of 0.05 or less were considered statistically significant. Bone loss over 
time was expressed as negative values. Because of skewed data, non-parametric tests were 
used in Paper I-III. 
2.3.1 Descriptive statistics 
Descriptive statistics were applied to calculate mean values and standard deviation (SD) or 
median values and interquartile range (IQR, 25-75 percentiles) when appropriate, and as 
numbers and percentages for counts (Paper I-III). 
2.3.2 Group analyses 
Wilcoxon test for two related groups were used to evaluate changes within groups during the 
observation time (Paper I, II, III). For comparison between groups Mann-Whitney U test were 
used for two independent samples (Paper I, II, III) and Kruskall-Wallis tests for more than 
two independent samples (Paper I and III).  In Paper III comparisons of changes in DXR were 
conducted using methodologies employed in the original PREMIER study (108). Instead of 
using three group comparison between the three treatment groups, two groups were compared 
in a hierarchical order with the Mann-Whitney U test, i.e. two-sided comparison of the 
combination group vs. MTX, followed by two-sided comparisons between the adalimumab 
monotherapy and MTX monotherapy treatment arms, and finally two-sided comparisons 
between the adalimumab monotherapy and the combination group. Each pair-wise 
comparison was completed only if the previous comparison was statistically significant. This 
approach was applied in the original PREMIER study because the main objective was to look 
for differences between the MTX group and the combination group. Chi square was used in 
Paper III to examine differences between categorical variables. 
2.3.3 Correlation 
Bivariate correlations using Spearman’s correlation were used in Paper I-III, both to examine 
the correlation coefficient (r) between DXR and other variables and to select independent 
variables for the multivariate models. 
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2.3.4 Multivariate analyses 
Multivariate linear regression analyses were used in Paper I-III. In Paper I DXA-BMD, DXR-
BMD and DXR-MCI was used as dependent variables, in Paper III DXR-MCI, while change 
in vdH Sharp score was set as dependent variable in Paper II. Independent variables were 
either selected from the bivariate correlation analyses or by clinical judgement. 
In Paper II multivariate logistic regressions were used because the dependent variable 
was dichotomised (increase in radiographic damage versus no increase in radiographic 
damage). From this logistic regression model a probability score was calculated to assess the 
risk of radiographic progression dependent on the combination of hand BMD loss, early 
radiographic damage and anti-CCP.  
2.3.5 Precision  
Differences between precision for the four digitised equipments were calculated according to 
Levene’s test for variances in the in-vitro study. Bonferroni approach was used to adjust for 
multiple comparisons. Standard deviation (SD) and coefficient of variation (CV %) defined as 
(SD/ mean) x 100 was analysed. The measurement error was calculated using Bland Altman 
95 % limits of agreement method (130). This gives an absolute and metric estimate of random 
measurement error, also called smallest detectable difference (SDD). Most disagreements 
between measurements are expected to be between these “limits of agreements” defined as 
d±z (1-Į/2) x SD, where d is the mean difference between the measurements and z (1-Į/2) is the 
100(1-Į/2)th centile of the normal distribution. The mean difference (d) is expected to be 0 
because we do not assume a true change in BMD to occur between the measurements 
(130;131).
In the in-vivo study the same parameters were calculated, but the standard deviation 
difference (SDdiff) was used because only two measurements of several different patients were 
performed. The other calculations are based on SDdiff . We also calculated the least significant 
change (LSC %) defined as the smallest percentage change that can be considered to be 
statistically significant  in an given individual (132;133).
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Equations used in the precision study (Paper IV): 
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n= number; d= difference; = measurement i of n=j; ijx x = mean of the measurements 
z (1-Į/2)= 100(1-Į/2)th centile of the normal distribution 
a1= measurement 1, a2= measurement 2 in the same patients 
Ma= mean of the first measurements, Mb= mean of the second measurements 
2.4 Ethical aspects 
Study I and II and the in-vivo part in study IV were approved by the regional committee for 
ethics and medical research. The Norwegian Data Inspectorate has approved the registry of 
RA patients in Oslo. Concerning the PREMIER study this was approved by a central 
institutional review board and independent ethics committee at each participating site (108).
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3. SUMMARY OF RESULTS 
3.1 Paper I: 
Hand bone loss as outcome measure in established rheumatoid 
arthritis. A two-year observational study comparing cortical and 
total bone loss
The objective of this two year longitudinal observational study was to explore hand bone loss 
as disease outcome measure in established RA.  
Hand bone loss was measured by both DXA and DXR. DXR was used to measure 
cortical hand BMD and MCI, whereas DXA was used to assess whole hand BMD. Only 
patients with performed DXA and DXR from both hands were included. 215 patients from the 
Oslo RA register (170 women and 45 men) with median disease duration of 9 years were 
included. This cohort was a part of a previous study (120), which examined 2-year bone loss 
at hip and spine in 366 RA patients. 
This study applying two different quantitative bone measure methods had two main 
findings: First, total hand bone loss measured by DXA-BMD seemed to occur only in the first 
years of the RA disease (-0.96 % for patients with disease duration three years or less vs. 0.24 
% in patients with disease duration over three years, p<0.01), whereas DXR-BMD measured 
cortical hand bone loss occurred both in early as well as late stages of the disease (-0.46 % vs.
-0.93 %, p=0.76). Change in DXR-MCI was highly correlated to DXR-BMD (r=0.94, 
p<0.001). Second, disease activity expressed as DAS28 independently predicted loss of DXR-
BMD but not changes in the DXA-BMD hand in the multivariate analysis. MHAQ and use of 
DMARD, prednisolone or anti-resorptive osteoporosis treatment did not influence the change 
of either DXA-BMD or DXR-BMD. 
This was the first study to compare DXR-BMD and DXA-BMD loss in RA patients 
with both early and longstanding disease.
The conclusion was that DXA-BMD can only be used as an outcome measure in early 
RA, whereas DXR-BMD may be appropriate as a marker for disease activity during the whole 
disease course. 
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3.2 Paper II:
Cortical hand bone loss after 1-year in early rheumatoid arthritis 
predicts radiographic hand joint damage at 5-year and 10 year 
follow-up
The objective of this 10-year longitudinal study was to examine one year hand bone loss in 
early RA as a predictor of radiographic damage at 5 and 10 years follow-up.  
A total number of 136 RA patients with early RA (disease duration 0-4 years, mean 
2.2 years) were followed with clinical data and hand radiographs. Joint damage was scored 
according to the van der Heijde modification of the Sharp method (vdH Sharp score), and 
hand BMD was assessed by DXR-BMD.
Patients with DXR-BMD loss at one year (exceeding the measurement error of the 
method) had a significant higher median increase in vdH Sharp score compared to patients 
without loss at both 5 (12 vs. 2 units) and 10 years follow-up (22 vs. 4 units). Hand DXR-
BMD loss was an independent predictive factor for radiographic damage when adjusted for 
other known predictors such as CRP, anti-CCP, IgM RF and baseline radiographic damage, 
both measured as absolute bone loss and dichotomised as hand bone loss versus not hand 
bone loss. An algorithm was made for the three risk factors: Anti-CCP, radiographic damage 
at baseline and DXR-BMD loss the first year of follow–up. If one risk factor was present the 
probability for radiographic damage at 10 years was 30-34 % and if two risk factors were 
present the respective value increased to 60-64 %. The presence of all three risk factors had a 
probability of subsequent radiographic progression of 87 % at 10 years.  
The conclusion of this study was that early hand bone loss measured by DXR-BMD 
was an independent predictor of subsequent radiographic damage. The predictive power of 
DXR-BMD was comparable to other biomarkers that are well known predictors of 
radiographic joint damage as e.g. anti-CCP and CRP. Our findings support that quantitative 
hand bone loss in RA precedes radiographic joint damage and may be used as a tool for 
assessment of bone involvement, especially in early RA.
43
3.3 Paper III:
Adalimumab therapy reduces hand bone loss in early rheumatoid 
arthritis: Explorative analyses from the PREMIER study  
The objective of this study was to examine the effect of anti-TNF therapy on hand 
osteoporosis and to identify predictors of hand bone loss. The basis for these analyses was the 
PREMIER study which was a 2-year year longitudinal double blind randomised clinical trial. 
The effect of adalimumab on hand bone loss was examined and related to radiographic joint 
damage in the three treatment arms of the PREMIER study: Adalimumab plus MTX, 
adalimumab and MTX monotherapy. A total of 768 patients were included at baseline and 
537 completed 2 years. The included patients had high disease activity (inclusion criteria: 8
swollen joints; ESR 28 mm/h or CRP 1.5 mg/dl; presence of erosions or RF), disease 
duration less than three years and they had never received MTX. Hand bone loss was assessed 
by DXR on the same hand radiographs which had been scored with modified Sharp score at 
baseline, 26, 52 and 104 weeks. DXR-MCI was chosen as the main bone measure, due to the 
technical challenges with the analyses of DXR-BMD (described in detail in section 2.1.3 The 
PREMIER study sample). 
The main finding in this study was that percentage hand bone loss both at 26, 52 and 
104 weeks follow-up was lowest in the combination group (-1.15; -2.16; -3.03 at 26, 52 and 
104 weeks) and greatest in the MTX group (-1.42; -2.87; -4.62) with figures in between for 
the adalimumab group (-1.33: -2.45; -4.03). The order of hand bone loss across the three 
treatment arms was similar to the order of radiographic progression. In multivariate analyses 
older age, elevated CRP, and non-use of adalimumab were independent predictors of hand 
bone loss.
We concluded that the results supported a similar pathogenic mechanism for hand 
bone loss and erosions in RA. The combination of adalimumab and MTX seemed to arrest 
hand bone loss less effectively than radiographic joint damage. Thus quantitative measures of 
osteoporosis may be a more sensitive tool for assessment of inflammatory bone involvement 
in RA.
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3.4 Paper IV:
Short-time in-vitro and in-vivo precision of direct digital X-ray 
radiogrammetry  
The aim of this study was to examine in-vitro and in-vivo precision for the new direct digital 
version of DXR, a development of the conventional DXR.
This study consisted of both an in-vitro and an in-vivo part. The in-vitro precision was 
tested on four different X-ray equipments, based on 31 radiographs of the same phantom. The 
in-vivo precision was based on duplicate hand radiographs from both hands in 39 individuals. 
The in-vitro precision ranged from 0.14-0.30 % expressed as coefficient of variations 
(CV %) and from 0.0012-0.0028 g/cm2 expressed as smallest detectable difference (SDD). 
The precision and the resolution of the radiographic equipment was strongly correlated 
(r=0.95, p=0.05). The corresponding values for the in-vivo precision for mean values of both 
hands were 0.46 % for CV %; 0.0046 g/cm2 for SDD and 1.28 % for LSC %. The precision 
was better when the mean of both hands was used than the non-dominant hand alone.  
The conclusion of this study was that the precision for direct DXR was highly 
satisfactory both in-vitro and in-vivo. Another important observation was that DXR-BMD 
values may differ between the X-ray equipments. Follow-up measurements in single 
individuals are therefore recommended to be performed with the same X-ray equipment to 
achieve the best precision.
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4. DISCUSSION 
The methodological strengths and limitations of this thesis are discussed in the first part of the 
discussion. The second part addresses the interpretations of the main results. 
4.1 Methodological issues 
4.1.1 Study design 
This thesis consists of two longitudinal observational studies (Paper I and II), one double 
blind randomised study (Paper III) and one cross-sectional study (Paper IV). 
Paper I-III had a retrospective longitudinal study design. The research questions were 
addressed after the data collection had been performed, and as a consequence, other variables 
than those chosen for the original studies were not available. The limitation of a retrospective 
study design also affected the hand bone density measurements, the primary outcome in this 
thesis, since the technical condition for the radiographs used for the DXR-BMD 
measurements had not been predefined - as will be further discussed below. 
However, the hypotheses for the different papers were set as for a prospective study, 
and the calculations for treatment effects in Paper III were performed blinded. The use of the 
DXR method allowed us to study hand bone density on hand radiographs despite that hand 
bone density was not part of the initial study design or data collection in Paper II and III. This 
advantage of the DXR method gave us the opportunity to use data from previously conducted 
studies and to obtain quick answers on interesting research questions without building up a 
new longitudinal cohort. 
In paper IV both the in-vitro and in-vivo short-time precision for direct DXR (dxr-
online) were analysed. The dxr-online method is a further development of the Pronosco X-
posure system. Because the clinical use of DXR-BMD is based on changes over time, we 
have also initiated a long-term precision study. 
4.1.2 Bias 
4.1.2.1 Selection bias 
Selection biases are distortions that result from procedures used to select subjects and from 
factors that influence study participation (134). Such biases may have had an impact on all 
four Papers in this thesis. In Paper I the 215 participants were recruited from a cohort of 366 
RA patients (120), Figure 2. Although the 366 patients from the original cohort was found to 
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be representative for the underlying RA population in Oslo (120), the 215 included patients in 
the present study had shorter disease duration, lower disease activity measured by DAS28, 
lower global assessment and used less prednisolone compared with those who were not 
included. In addition a conservative inclusion was performed in the study. Only patients with 
hand radiographs and measurement of DXA-BMD hand at baseline and 2-year follow-up for 
both hands were included. Another approach could have been to include patients with 
radiographs from one hand missing and used the available hand at all time points (this 
approach was used in Paper III). The approach in Paper 1 could have led to an exclusion of 
the most severely diseased patients with metal implants in hands or severely deformed hands 
– which would not be eligible for analyses by DXR. Further, patients older than 70 years were 
excluded. All this examples of selection bias may have influenced the relative small changes 
observed in Paper I. 
In Paper II the major limitation was that only 163 of the 238 included patients had 
radiographs at baseline. Further, patients older than 70 years, and patients classified as stage 
IV according to Steinbrocker’s functional class (80) were excluded from recruitment to the 
study. Due to the long observational time, 89 patients were lost from baseline to follow-up 
due to death (N=35), illness, reluctance to participate and moving out of the area. Further, 
seven radiographs could not be analysed for DXR-BMD (six were underexposed and one had 
metal in the metacarpal bone). 
Loss of patients at follow-up was also a problem in Paper III. Compared to the original 
PREMIER study we missed 31 patients at baseline and two at 2-year follow-up due to lack of 
X-rays. In the original PREMIER study there were 260 withdrawals (77 due to an adverse 
effect; 111 due to lack of effect; and 72 patients dropped out without known reason).
In Paper IV precision was calculated only in healthy individuals and not in RA 
patients, which may be a limitation as it is suggested that the precision of DXR may be poorer 
in RA patients due to deformities and inflammation of the hand (126;135). However, for the 
DXR Pronosco X-posure system we have previously presented at the EULAR 2008 
conference precision data calculated from RA patients (126) which did not differ substantially 
from previous precision reports on this method. 
4.1.2.2 Diagnostic bias 
To be included in Paper I, II and III the patients should fulfil the ACR criteria of RA (17). 
This may have led to an exclusion of patients with undifferentiated arthritis not yet fulfilling 
the ACR criteria for RA (136). In addition, inclusions based on classification criteria do not 
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have 100 % specificity. As a consequence, patients not having RA and patients with self-
limited RA may have been included. However, patients in the cohorts from the Oslo RA 
register and the EURIDISS study were examined by a rheumatologist before inclusion. 
The concept of early RA has changed since the inclusion of the patients in Paper II and 
III. When the EURIDISS study started in 1992 disease duration of four years or less was 
considered as early RA and according to the PREMIER study (with the protocol written in 
2000) a disease duration less than three years was defined as early RA. Focus is now on 
treatment of patients with very early RA (137) and probable RA (138) as well as identifying 
patients with risk of developing RA (139). However, in the PREMIER study the mean disease 
duration for the participants were only 9.1 months, which in our opinion justify using the term 
“early RA”. 
4.1.2.3 Confounding bias  
Confounding may be considered as a confusion of effects (134). For example high 
inflammation at baseline leads to increased radiographic damage in joints, but it also leads to 
increased bone loss. It is therefore important to adjust for high inflammation if we examine 
the effect of early bone loss on radiographic damage. In Paper II we made a multivariate 
model for radiographic damage, and in Paper I and III we made multivariate models for 
factors affecting bone loss. We have adjusted for confounding factors by using correlation 
analyses and clinical judgement. None of our models are fully explainable which means that 
there are unmeasured and unknown factors affecting bone loss that we have not revealed 
(residual confounding). 
4.1.3 Representativeness 
A central question in this thesis is if the results can be generalised and are valid for the RA 
population. The three different cohorts differed with regards to disease activity and disease 
duration (Table 6). The cohort in Paper I was from the Oslo RA register. A population study 
from 1994 supported that the Oslo RA register had an 85 % completeness (3;140) and that the 
register was representative of the entire RA population in Oslo. As discussed in 4.1.2.1 the 
patients in the present cohort had shorter disease duration and lower disease activity than the 
original cohort, but are most likely representative for the general RA population. 
The patients included in the EURIDISS cohort were recruited from ordinary out-
patients’ clinics at the Diakonhjemmet Hospital and Martina Hansen Hospital with no strict 
inclusion criteria except that disease duration should be 4 years or less and the patients had to 
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fulfil the ACR classification criteria for RA (17). The patients were consecutively included 
and it is likely that also this cohort represent a broad spectrum of rather unselected RA 
patients. In this study 62 % were positive for anti-CCP, while 48 % were positive for RF. The 
proportion of RF positive patients correspond to the Oslo RA register, which also supports 
that EURIDISS cohort represent a broad spectre of the RA population (141). 
The patient cohort in the PREMIER study (Paper III) included selected MTX naïve 
adult RA patients (>18 years) with very high baseline disease activity and short disease 
duration (<3 years). To meet these inclusion criteria, 133 investigational sites in Europe, 
North America and Australia were involved to include a sufficient number of patients. This 
cohort reflects the most severe patients with early RA. A similar cohort could probably not be 
established now in Western Europe because of the improved access to modern, effective 
therapies. 
Due to the different patient cohorts in this thesis as described above, the patients may 
not reflect the entire RA population and thus the results from this thesis may not be universal 
for all RA patients. However, high disease activity was a predictor for DXR-BMD and DXR-
MCI loss in both the cohort from the Oslo RA register and the PREMIER cohort. This finding 
suggests that the inflammatory disease process in RA is an important factor for hand bone loss 
in RA patients across different levels of disease activity and disease durations. 
4.1.4 Bone measurements and imaging 
The main method for bone measurements in this thesis was the DXR method, and DXR was 
compared with DXA only in Paper I. The examinations of patients in the Oslo RA register in 
1996-97 and 1998-99 had a focus on bone measures and included DXA measurements at 
various sites (120;142). DXA measures total bone and is based on X-ray absorptiometry, 
whereas DXR is based on geometric measures and linked to DXA through a density constant 
(see also part 2.2.2.1 and 2.2.2.2). We did not have the possibility to examine DXA-BMD 
hand in Paper II and III, since DXA was not available at Diakonhjemmet Hospital when the 
EURIDISS cohort was established and was not used in the PREMIER study. However, access 
to DXA measures would have been particularly interesting in these cohorts with shorter 
disease duration than the patients in Paper I, since DXA hand bone loss has been shown to be 
most pronounced in the first 2-3 years of the inflammatory disease process in RA (24). 
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4.1.4.1 DXA 
DXA is considered as the gold standard among the bone density measurements, however the 
method do have limitations. DXA can not separate cortical and trabecular bone. The measure 
is planar (even if it is expected to give information about a volumetric measure), it is sensitive 
to calcium only, and the method does not give any information about the bone architecture or 
the collagen quality (143). The DXA bone density result is also influenced by soft tissue and 
marrow fat. Use of corticosteroids has been shown to increase fracture risk very rapidly after 
initialisation, before changes are measurable with DXA (144). This observation suggests that 
DXA does not capture the whole spectrum of bone strength. However, DXA is still 
considered as the best BMD measurement due to low radiation dose, feasibility, relative good 
precision and a good prediction of fractures (145). 
As mentioned in chapter 2.2.2.2, DXA-BMD can be measured either around selected 
finger joints or by using whole hand. We chose to measure whole hand because this is more 
feasible in addition to reflect the total inflammation at the hands (146). Another objection may 
be that bone mineral content (BMC) should have been presented. BMC is not dependent of 
the area. Among RA patients with hand deformities the precision of BMC has not been found 
to be influenced by the position of the hand, in opposite to BMD (70;143). In figure 8 the 
cumulative probability plot of DXA-BMD, DXA-BMC and DXR-BMD percentage change 
from the patients in the Oslo RA register is presented (Paper 1).There is nearly a complete 
overlap between DXA-BMC and DXA-BMD which suggests that DXA-BMC does not give 
any major additional information on hand bone than DXA-BMD. 
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Figure 8. Cumulative probability plot of bone density percentage changes in Paper I. 
4.1.4.2 DXR 
The major limitation for DXR is that only cortical bone is measured. Further, the method can 
not recognise the metacarpals in patients with severe deformations or in patients with metallic 
implants, which may represent a bias by excluding the most disabled patients. 
One main advantage of the DXR-method is that BMD and MCI is measured on hand 
radiographs which make it possible to do research on existing cross sectional and longitudinal 
cohorts. The DXR method is also very simple to use and have a good precision. In addition 
the Pronosco X-posure system used in Paper I and II is robust. Less than 1 % of the images 
analysed in Paper II were missed due to underexposed radiographs, metal in the metacarpal 
bone or deformities. 
The calculation of DXR–BMD is based on volume per area and requires a known 
resolution, since a distance in a digitized radiograph cannot be measured when the resolution 
is unknown. This turned out to be a major challenge in Paper III, as mentioned in section 
2.1.3. Ideally, DXR-BMD was intended to be the main outcome measure, but because of 
unknown resolution of many radiographs, DXR-MCI was used as the major hand bone 
measurement outcome. DXR-MCI is based on the ratio and not on absolute measures. By 
using DXR-MCI instead of DXR-BMD we lost the opportunity to correct for porosity. 
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Further DXR-BMD can be calibrated for blurring and particular qualities of the different 
radiographic measurement equipment. An old study from 1969 has even indicated that the 
correlation between ash mineral content and cortical area was better than between ash mineral 
content and cortical ratio indicating that DXR-BMD reflects bone mass better than DXR-MCI 
(147). However, DXR has improved the precision of MCI and a highly significant and strong 
correlation between DXR-MCI and DXR-BMD in cross-sectional studies has been found 
(r=0.90, p<0.01) (77). In Paper I we found a highly significant and strong correlation for 2-
year change between DXR-MCI and DXR-BMD (r=0.94, p<0.001) (123). Both DXR-BMD 
and DXR-MCI were greatly correlated to DXA-BMD hand (123). On the basis of these 
observations we consider DXR-MCI to be a valid surrogate measure of hand bone mass 
change.
DXR measures the narrowest part of the metacarpal bone and not exactly the 
periarticular bone. This may theoretically be a limitation of the DXR-BMD method’s ability 
to assess bone changes directly related to synovitis in the joints (62). However, the 
metacarpals will be influenced by the inflammation both in the MCP-joints and the wrist. 
Thus, the cortical bone loss may be considered to reflect overall joint inflammation in the 
hand.
4.1.4.3 Radiographs 
Radiographs have traditionally been used to detect joint damage in RA and are considered as 
the gold standard for imaging in RA (148). However, recent studies have demonstrated that 
both US and magnetic resonance imaging (MRI) are more sensitive modalities in detecting 
erosions (148;149). Based on these facts, it would have been of interest to compare DXR with 
US and MRI. When the EURIDISS study started in 1992 conventional X-rays was the 
available method for assessing damage and this method was also applied for the 10-year 
follow-up. For the PREMIER study, radiographs were also used for assessment of joint 
damage. The use of US and MRI in clinical trials has been limited, mainly due to lack of 
validated scoring methods and due to feasibility. 
The radiographic scorings methods were different in Paper II and III, which is not 
optimal, but the radiographs in Paper III (PREMIER) were already scored when we got the 
opportunity to analyse hand bone with DXR (Table 5). In Paper II only radiographic scoring 
results of hands were used because only hand radiographs were available. In Paper III 
combined results from hands and feet were used, which may have influenced the correlation 
(r) between change in DXR and radiographic damage. In Paper II the correlation (r) between 
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change in DXR and radiographic damage was -0.35 at 1 year and -0.47 at 2 year whereas in 
Paper III the corresponding numbers were -0.23 at 1 year and -0.32 at 2 year. The fact that 
DXR-BMD was used in Paper II while DXR-MCI was used in Paper III, in addition to higher 
radiographic damage score at baseline and shorter disease duration among the patients in 
Paper III, may also have influenced the correlation. 
4.1.5 Clinical measures  
The collected disease variables in Paper I-III differed and were collected at different time 
points. Thus, we have limited opportunities to compare the cohorts in this thesis. One example 
of inconsistencies in the data collection is that swollen joint count was not recorded at the 
baseline and 1-year follow-up visit in the EURIDISS cohort (Paper II) which excluded 
calculation of DAS28. CRP and ESR were therefore used as markers of inflammation and 
disease activity. Further, two different forms of HAQ questionnaires were used. In Paper II 
and III the HAQ ranging from 0-3 was performed (108;150), while in Paper I the modified 
HAQ (MHAQ, range 1-4) was used (26). Both the HAQ and MHAQ measure the extent of 
disability within 8 components of daily living, but in the MHAQ the number of item is 
reduced from 20 to 8 (151). 
4.2 Results: Interpretations and comparison with other studies 
4.2.1 The magnitude of bone loss: Comparison of the different cohorts 
(Paper I, Paper II, Paper III) 
Bone loss over two year is depicted in Figure 9 in the different cohorts, both as DXR-BMD 
(Figure 9a) and DXR-MCI (Figure 9b). Both DXR-BMD loss and DXR-MCI loss were 
greatest in the group receiving MTX in the PREMIER cohort. 
In Paper I the changes in DXR-BMD and DXR-MCI were small, both compared to the 
other cohorts in this thesis and previous studies (Table 1) (20;102). The main reason for this 
observation is most likely due to differences between patients included in the various studies 
with regards to disease activity and disease duration. The cohort in Paper I from the Oslo RA 
register was representative of the underlying patient population, and patients with mild RA 
disease dominated the number of included patients in this study. In addition, some of the most 
diseased patients may have been excluded, as previously discussed in section 4.1.2.1. Further, 
the disease duration was prolonged (median 9 years, mean 12 years), and both DXA-BMD 
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(24) and DXR-BMD (102) changes have been found to be greatest early in the disease. 
Böttcher et al reported annual DXR-BMD loss in the first six years of the disease to be as 
high as 11 %, with a subsequent decline to 3-4 % over the next years (102). 
Figure 9. 2-year changes in DXR in the different rheumatoid arthritis cohorts. 
a) Changes in DXR-BMD. 
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To evaluate so small changes as in Paper I, the influence of normal bone loss, which 
takes place also in healthy adult subjects, is important. Normal bone loss for DXR-BMD has 
only been examined in cross-sectional studies showing an annual rate of bone loss between 
0.4 and 0.9 % (95-98). In a 4-year longitudinal study comparing cross-sectional versus 
longitudinal evaluation of bone loss (measured by DXA-BMD), cross-sectional studies were 
overestimating the longitudinal loss in hip and spine, but not in the distal ulna and radius 
(152). The hand was not included in this analysis. However, age was not a significant 
predictor for hand bone loss over 2 year, neither for DXR-BMD nor DXA-BMD, in the 
multivariate model in Paper I (data not shown). The age of the cohort ranged from 22-70 year 
and it is difficult to estimate a mean normal bone loss for a so heterogeneous cohort with 
regard to age. A peak bone mass for DXR-BMD and DXR-MCI is found to be reached in age 
group 40-49 years (96;97). Thus the youngest age group should normally still have gained 
bone (95-97). Further a 10-year longitudinal study has suggested that the menopause, and not 
age per se, determines the start of a period with increased rate of cortical bone loss (153). We 
had information of menopausal status in Paper I, but it did not influence the multivariate 
model (data not shown). In Paper II and III we did unfortunately not have information 
regarding menopausal status. 
The DXR loss in Paper II (the EURIDISS cohort) and Paper III (the PREMIER 
cohort) was more comparable to the loss in other studies (20;93;100;101). The patients in 
these two studies did also have high disease activity and shorter disease duration. 
4.2.2 The precision of DXA and DXR (Paper I, Paper II, Paper III Paper IV) 
With the relative small DXR-BMD changes, especially in Paper I, in addition to the technical 
challenges with the measurements as reported in Paper III, a precision study for DXR was 
considered to be of importance. A premise to use DXR on the individual level is that the 
technique has a sufficient precision to capture small changes and that these changes can be 
considered as true (i.e. the change in the individual has to be greater than the measurement 
error for the method). 
In Table 3 precision from previous studies are depicted. The precision (CV %) of 
DXA-BMD has been found to be about 0.8-1.4 % for whole hand (71;72;114;115) and 0.9-4.5 
around joints (71;72;90;128). For DXA-BMC the respective values are 2.3-3.3 % (70;72) and 
1.4-3.3 (127). 
Most of the precision data for DXR has been performed on Pronosco X-posure version 
1.0 that included ulnae and radius as well as metacarpi 2-4. We calculated the precision data 
55
on Pronosco X-posure version 2.0 in 28 healthy individuals and 37 RA patients (each 
individual performed two radiographs with reposition) (126) and reported results both for 
DXR-BMD and DXR-MCI. The precision for Pronosco X-posure version 2.0 was satisfactory 
and better than the precision both for DXA-BMD whole hand and DXA-BMD around single 
joints (Table 3). The precision increased when using mean of both hands instead of non-
dominant hand and it seemed that the precision was poorer in patients with RA than healthy 
individuals. These data have not been published in a peer-reviewed journal due to the fact that 
the Pronosco X-posure system is no longer available, but has been replaced by the dxr-online 
system. 
Table 6. The precision of Pronosco X-posure version 2.0 (own data (126)).
Healthy individuals (N=28) 
DXR-BMD (g/cm2) DXR-MCI (ratio) 
Non-dominant
hand
Mean both 
hands
Non-dominant
hand
Mean both 
hands
Mean (SD) 0.601 (0.065) 0.612 (0.067) 0.479 (0.057) 0.481 (0.057) 
SD difference 0.0025 0.0017 0.0024 0.0015
SDD ±0.0048 ±0.0033 ±0.0047 ±0.0030
CV % 0.41 0.28 0.50 0.31
LSC % 1.13 0.78 1.39 0.87
Rheumatoid Arthritis patients (N=37)
Mean (SD) 0.512 (0.109) 0.515 (0.107) 0.380 (0.084) 0.379 (0.080) 
SD difference 0.0030 0.0024 0.0025 0.0021
SDD ±0.0059 ±0.0047 ±0.0050 ±0.0041
CV % 0.59 0.47 0.67 0.55
LSC % 1.64 1.30 1.86 1.53
N= number; DXR= digital X-ray radiogrammetry; BMD= bone mineral density; MCI= metacarpal 
cortical index; DXA dual energy X-ray absorptiometry; BMC= bone mineral content; SD= standard 
deviation; CV= coefficient of variation; SDD= smallest detectable difference; LSC %= least 
significant change. 
For dxr-online, no precision data had been published prior to this thesis, except data 
available from the manufacturer. In the frame of this thesis we therefore conducted a short-
time precision study. The results from this study (Paper IV) showed that the precision for 
direct DXR was at least as good as for the Pronosco X-posure system with a CV % ranging 
from 0.14 % to 0.30 %. An important message from this study was that the same radiographic 
equipment for follow-up should be used because of possible differences in bone density 
56
measurements between the radiographic equipments. In our study the DXR-BMD for one of 
the equipment differed 1.1 % from the mean DXR-BMD, which may be due to the different 
ability among the radiographic equipments to recognize porosity due to resolution capacity. 
4.2.3 DXR and DXA as outcome measure in rheumatoid arthritis (Paper I, 
Paper III) 
The most surprising finding in Paper I was that DXA-BMD loss in hands only occurred in the 
first years of the disease, but not in patients with established disease, whereas a significant 
bone loss was seen for DXA-BMD at hip and spine and DXR-BMD, independent of disease 
duration (120;123). A discrepancy in loss of DXA-BMD hand between early and long-
standing disease has previously been suggested based on the results of two longitudinally 
studies (24;91). Degenerative bone changes and increased inflammation in the small joints of 
the hand in the first years of the disease has been suggested partly to explain this finding (70). 
As DXA measures both trabecular and cortical bone a third explanation could be that the rate 
of trabecular and cortical bone loss is different in early versus late stages of the disease. The 
fact that the two methods for bone measurements are based on completely different 
techniques and that the precision for the DXR-method (76;126;154) is superior to the DXA 
method (71;72;115) may also contribute to the explanation. In another 2-year longitudinal 
study of early RA no changes in DXA-BMD hand was found (20). 
The study reported in Paper I is the first study to evaluate DXA-BMD and DXR-BMD 
loss as outcome measures in RA with both early and established disease. In the few previous 
studies which have compared DXR and DXA hand in early disease the authors have 
concluded that changes in DXR is more sensitive than DXA to disease activity (20;112). 
DXR is evaluated as an outcome measure both in early RA in Paper III (DXR-MCI) 
and in established RA in Paper I (DXR-BMD and DXR-MCI). DXR-MCI was found to be 
highly correlated to DXR-BMD in Paper I (r=0.86 at baseline and r=0.94 for percentage 
change over 2-year) (123). DXR turned out to be dependent of disease activity in both stages 
of the disease duration. DAS28 was the strongest predictor for DXR-BMD and DXR-MCI 
loss in Paper I, while in Paper III CRP together with non use of adalimumab and older age 
predicted DXR-MCI loss and DAS28 was borderline significant. These similar findings 
observed in two different cohorts support that DXR hand bone loss reflects the extent of the 
inflammatory activity in RA and thus may be a promising outcome measure of bone 
involvement in RA. 
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4.2.4 The effect of anti-TNF therapy on bone loss (Paper III)  
Anti-TNF therapy has been found to significantly reduce the progression of radiographic joint 
damage in RA patients (88;104-108). Studies have also suggested that anti-TNF therapy may 
prevent general bone loss (109-111;155). Further, RA patients treated with anti-TNF therapy 
has been shown to have a lower rate of bone loss at spine and hip than at hand (93;110). Hand 
bone loss did also precede generalised bone loss (93), as has also been observed in RA 
patients not treated with anti-TNF therapy (21;92). 
In a 2 year longitudinal treatment strategy study (the BeST study), RA patients treated 
with anti-TNF therapy or high dose prednisolone was shown to have a lower rate of bone loss 
at hand than patients treated with conventional DMARDs (93). Use of anti-TNF therapy had a 
positive effect on periarticular bone in another study which employed quantitative ultrasound 
(QUS) (155). Our findings support that treatment with anti-TNF therapy reduces hand bone 
loss. Further, the order of hand bone loss across treatment arms was similar to the order of 
radiographic progression support that erosions and bone loss are caused by the same cellular 
mechanism involving the osteoclast activated by the inflammatory RA disease process. 
Recent results from a study of the RANKL inhibitor denosumab further support this 
mechanistic hypothesis since this drug inhibited erosions (52) and hand DXA-BMD loss 
(156), but not cartilage destruction (52). 
As described in chapter 1.1.3, TNF-Į stimulates RANKL by cytokines in addition to 
stimulate the osteoclast formation directly (44;49;50). This may explain why TNF-Į can 
reduce bone damage even if the disease activity remain moderate to high in the patients. This 
phenomenon is called “uncoupling”, i.e. some cytokines trigger the inflammation, while 
others seem to be more important for bone destruction. Further TNF-Į seems to hamper the 
osteoblast activity (53). Blocking TNF-Į will therefore decelerate bone destruction by 
influencing both the osteoclast and the osteoblast. 
4.2.5 DXR-BMD as a predictor for radiographic damage (Paper II) 
As previously stated periarticular osteoporosis has been known as a hallmark for RA and it is 
included as one of the ACR criteria of bone involvement beside erosions in RA (17). Further, 
periarticular osteoporosis on radiographs has been observed to precede the development of 
erosions (18;19) When this thesis started, the results from only one longitudinal pilot study 
had indicated that DXR-BMD loss in RA patients the first year of follow-up was a predictor 
of subsequent radiographic damage (100). The result from Paper II has confirmed the result 
from this pilot study. In our study DXR-BMD loss the first year of follow up was an 
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independent predictor for subsequent radiographic damage at 5 and 10 year, even when 
adjusted for other known predictors of radiographic progression as e.g. baseline radiographic 
damage, anti-CCP and markers of inflammation. 
General bone loss has also been found to be influenced by disease activity (157), and it 
would have been of interest to examine if the loss in DXR-BMD was a part of the general 
bone loss or if it was specific for the hand. Unfortunately, DXA hip and spine measurements 
were not available in the EURIDISS cohort. As described in chapter 1.1.6.1, hand bone loss in 
early RA has been shown to occur more rapidly than bone loss in hip and spine (21;92;93). 
Hand BMD loss has also been found to be greater than BMD loss in hip and spine (93) and 
radiographic joint damage has been shown to be more strongly correlated with low hand 
DXR-BMD than DXA-BMD at hip and spine (77;94). All this findings suggest that hand 
bone loss is more influenced  by inflammation, while generalised bone loss may be more 
associated with the prolonged course of RA, including use of corticosteroids and immobility 
(26).
 In the multivariate linear regression model in Paper II the absolute DXR-BMD loss at 
one year was an independent predictor for radiographic damage at 5 and 10 year. The absolute 
vdH Sharp score at baseline was the most important predictor for the damage status at 5 and 
10 year, i.e. if the radiographic damage is high at baseline it will also be high after 5 and 10 
year. If the model were performed without anti-CCP or DXR-BMD respectively, the adjusted 
R square would have decreased about 2 % both at 5 and 10-years. Anti-CCP and DXR-BMD 
loss gave approximately the same contribution to the model. 
These findings emphasise that the degree of radiographic damage is still the best 
predictor for subsequent radiographic damage. But with the new possibilities for treatment it 
will be important with predictors that can give information before the radiographic damage 
have occurred. For this purpose both DXR-BMD and anti-CCP are important. They are both 
more feasible to use than radiographic scoring and DXR may be more sensitive to change 
than radiographic joint progression. Further, both the level of DXR-BMD loss (as shown in 
Paper II) and high level of anti-CCP has been demonstrated to increase the risk of 
radiographic damage(8). 
Only few of the patients in the EURIDISS cohort (Paper II) (N=7) did not loose DXR-
BMD the first year of follow-up, but still had a considerable increase in radiographic damage. 
The reason for this discrepancy is not clear. Subanalysis of these patients showed that five 
were women, mean age was 45.7 year, six had positive anti-CCP (five with a high level) and 
four had radiographic damage at baseline. Six of these patients had a significant bone loss at 
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two year suggesting a late bone loss. These observations emphasise that RA is a 
heterogeneous disease and there is a need to combine several predictors to give the 
opportunity for personalized treatment based on individual prognostic factors. 
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5. CONCLUSION AND CLINICAL IMPLICATIONS 
5.1 Answer to research questions 
We were able to provide answers to the research questions presented in section 1.2.2 
x Measurements of DXR-BMD and DXR-MCI can be used as an outcome measure both 
in early and established RA (Paper I and III), while DXA-BMD hand seems to be a 
valuable outcome measure in early RA only (Paper I). 
x In early RA DXR-MCI loss was predicted of CRP, older age and the none-use of 
adalimumab, while high DAS28 was borderline significant. In established RA DXR-
BMD loss and DXR-MCI loss was predicted by high disease activity (DAS28). Our 
results suggest that DXR-BMD is influenced by inflammation both in early and 
established RA and may be used in RA patients independent of disease duration.
The only predictor for DXA-BMD hand loss in established RA was short disease 
duration. Disease activity did not influence the DXA-BMD loss in established RA 
(Paper I and III). 
x Cortical hand bone loss was an early marker of bone involvement in RA (Paper II). At 
one year 67 % of patients had a DXR-BMD loss more than LSC (the measurement 
error for the method), while 46 % had an increase in vdH Sharp score more than 1 
unit.
x Cortical hand bone loss predicted subsequent radiographic damage both at 5 years and 
10 years follow-up. Both 1-year absolute change in DXR-BMD and 1-year change 
more than LSC were significant predictors of subsequent radiographic damage (Paper 
II).
x In our material the absolute value of DXR-BMD was a predictor for radiographic 
damage and was comparable to anti-CCP and inflammation measured by CRP, but not 
as good as the absolute radiographic damage (vdH Sharp score) at baseline. When 
dichotomised into bone loss vs. no bone loss, radiographic damage vs. no damage and 
anti-CCP positive vs. negative, the three predictors were comparable in strength 
(Paper II). 
x Anti-TNF therapy, in our study adalimumab, reduced the rate of cortical hand bone 
loss. Patients who received adalimumab and MTX in combination therapy lost 
significantly less bone compared with patients who received MTX monotherapy. Use 
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of adalimumab was also a protector for bone loss when adjusted for disease activity, 
age, gender, disease duration, radiographic damage and HAQ. 
x This thesis supports the hypothesis that erosions and osteoporosis are caused by the 
same cellular mechanism. Both the findings that cortical hand bone loss predicted 
subsequent radiographic damage combined with the fact that the order of hand bone 
loss across the three treatment arms (MTX vs. adalimumab vs. combination of MTX 
and adalimumab) was similar to the rate of radiographic progression support a 
common cellular mechanism, involving the osteoclast cell. (Paper II, III). 
x The short time precision (CV %) for the new direct DXR which calculated DXR-BMD 
from digitized radiographs of the same phantom (31 radiographs with reposition) 
ranged from 0.14-0.30 in four different radiographic equipments. This is considerable 
better than for DXA-hand where the CV % is about 1 %.  For healthy individuals (39 
individuals with 2 radiographs with reposition) the CV % was 0.46. The reason for the 
discrepancy may be due to that the phantom is fixed in one position in addition to the 
different numbers of radiographs taken. However, the precision both in-vivo and in-
vitro was highly satisfactory (Paper IV). 
5.2 Clinical implications 
In this thesis we have examined utilities for the DXR-BMD method that might be of clinical 
interest. We have shown that DXR-BMD hand bone loss was associated with markers of 
inflammation both in the early and established RA. These results suggest that DXR may be a 
possible outcome measure during the whole disease course in RA. In contrast, DXA-BMD of 
the hand seems to be valid as an outcome measure only in early RA. Further, our results have 
shown that hand bone loss in early RA was a predictor of subsequent radiographic damage 
and that the predictive power was comparable in strength to other predictors of joint damage 
as e.g. anti-CCP and CRP. Our study did also provide evidence that DXR-BMD could be used 
as response variable of bone involvement for potent anti inflammatory treatment. The 
predictive value of DXR combined with the ability of anti-TNF therapy to reduce both 
erosions and bone loss, suggest that DXR-BMD can be applied as a clinical tool to identify 
patients in need of potent biologic treatment. This thesis does also support the hypothesis of a 
common cellular pathway between radiographic erosions and bone loss, the two features of 
bone involvement in RA patients. We have also documented a highly satisfactory precision of 
the DXR method; both used on conventional and digitised radiographs.
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Based on the findings from this thesis together with other studies on DXR published 
over the last years(20;93;94;100-102;116) , the manufacturer Sectra has developed dxr-online 
as a prediction tool for joint damage in RA.  
 However, there are still some questions to be answered before the DXR-BMD method 
can be recommended for use in daily clinical care. First, the DXR-BMD measurements are 
based on changes over time and the patients need to take two DXR-BMD measurements to 
calculate the hand bone loss. There is no cut-off value defined as pathological which is a 
limitation compared with the scoring of radiographic joint damage. Thus more research to 
evaluate a clinical cut-off value is of importance. Second, the Pronosco X-posure system has 
been replaced by dxr-online which calculates DXR-BMD only, without providing other 
parameters as MCI, cortical thickness, bone width and porosity. It is not clear if DXR-BMD 
can substitute all these measurements which may be a limitation for the dxr-online system 
compared with the Pronosco X-posure system. Further, several small studies suggest that the 
DXR-BMD loss is higher in patients with RA than other rheumatic diseases (20;21;72), but 
this has not been validated in larger cohorts and should be examined. At last, there is a lack of 
data understanding the natural rate of DXR hand bone loss in the normal population which is 
a major limitation of the method. 
There is an increased focus on bone damage in RA among rheumatologists leading to 
an increased search for new tools for recognising bone involvement and therapy to reduce 
bone damage. We believe that this thesis increase our understanding and illuminates the 
possibilities of cortical hand bone loss, assessed by the DXR method, as a feature of 
inflammatory bone involvement in RA. 
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6. ERRATA 
PAPER III
Concerning the multivariate model in Paper III, the variable “Treatment group” were actually 
coded as a ordinal explanatory variable with the rank MTX - adalimumab - combination 
therapy and not as a dummy variable as stated in the paper. A multivariate model calculated 
with dummy variables is therefore presented in Table 7. There were no differences between 
using the variable “treatment group” as an ordinal explanatory variable or as a dummy 
variable with MTX as the reference value. 
Table 7. Predictors for percentage DXR-MCI loss at 104 weeks follow-up in 515 
rheumatoid arthritis patients explored by multivariate linear regression model.
DXR-MCI percentage change at 104 weeks
Beta p-value
Age, years -0.25 <0.001
Female gender -0.04 0.38
Disease duration, years 0.06 0.12
C-reactive protein, mg/l -0.23 <0.001
DAS 28 -0.09 0.07
Treatment group* 
x Adalimumab vs. MTX 
x Combination vs. MTX 
0.06
0.18
0.18
<0.001
R2, adjusted 0.19
* MTX used as reference treatment group. MCI baseline, Sharp score baseline and HAQ did not 
influence the model. 
DXR= Digital X-ray radiogrammetry; MCI= Metacarpal cortical index; HAQ= Health Assessment 
Questionnaire; DAS28= 28-joint disease activity score. 
64
7. APPENDIX 
PAPER III 
In Paper III calculations were performed for different parameters of DXR: BMD, cortical 
thickness (CT), width (W) and MCI were all analysed for the subgroup which had DXR-BMD 
measures (Table 8). DXR-CT followed the same pattern as DXR-MCI and DXR-BMD while 
DXR-W was stable for all time points and where not influenced by treatment. As this table in 
our opinion did not provide substantial and additional new information (and due to the 
maximal number of tables and figures allowed in Paper III) these data were published as a 
supplementary table for electronic publishing only. 
The values for DXR porosity index are not included in the table. This DXR parameter 
has in previous studies been shown to have considerable poorer precision than DXR-MCI and 
DXR-BMD (158) Thus, within the methodological limitations in this study, we found these 
data to be inconclusive. 
Table 8. The effect of methotrexate monotherapy, adalimumab monotherapy and 
adalimumab combined with methotrexate on different DXR parameters. Calculations 
are performed on the subgroup were DXR-BMD could be analysed.
MTX
Median (mean) 
percentage
change
Adalimumab
Median (mean) 
percentage
change
Combination
Median (mean) 
percentage
change
26 weeks -1.36(-2.04) -1.16 (-1.83) -1.11 (-1.66) 
52 weeks -2.70 (-3.65) -2.91 (-3.61) -2.16 (-2.89) 
DXR-MCI 
104 weeks -4.50 (-5.67) * -4.35 (-5.23) -3.60 (-4.26) 
26 weeks -1.20(-1.73) -0.96 (-1.46) -1.06 (-1.25) 
52 weeks -1.86 (-2.77) -1.97 (-2.70) -1.63 (-2.11) 
DXR-BMD 
104 weeks -3.58 (-4.22) ** -2.40 (-3.70) -2.49 (-3.07) 
26 weeks -1.53 (-2.14) -1.12 (-1.78) -1.34 (-1.80) 
52 weeks -2.81 (-3.61) -2.55 (-3.51) -2.22 (-2.76) 
DXR-
cortical
thickness 104 weeks -5.02 (-5.46)*** -3.92 (-4.92) -3.38 (-3.99) 
26 weeks -0.13 (-0.11) -0.10 (-0.01) -0.22 (-0.19) 
52 weeks -0.04 (0.07) 0.01 (0.09) 0.07 (0.13) 
DXR-
bone width 
104 weeks 0.18 (0.13) 0.30 (0.14) 0.17 (0.17) 
*     At 104 weeks the MTX group lost more DXR-MCI than the combination group (p=0.04) 
**   At 104 weeks the MTX group lost more DXR-BMD than the combination group (p=0.049) 
*** At 104 weeks the MTX group lost more DXR cortical thickness than the combination group 
(p=0.04)
DXR= digital X-ray radiogrammetry; BMD= bone mineral density; MCI= metacarpal cortical index; 
MTX= methotrexate 
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Abstract
The aim of this 2-year longitudinal observational study was to
explore hand bone loss as a disease outcome measure in
established rheumatoid arthritis (RA).
A cohort of 215 patients with RA (170 women and 45 men,
aged 20–70 years) were recruited from the Oslo RA registry
and studied for changes in hand bone mass during a 2-year
follow-up. Digital X-ray radiogrammetry (DXR) was used to
measure cortical hand bone mineral density (BMD) and
metacarpal cortical index, whereas dual-energy X-ray
absorptiometry (DXA) was used to assess whole hand BMD,
which measures total cortical and trabecular bone. DXA-BMD
total hip and spine and informative data for disease and therapy
were also collected.
Hand bone loss could be revealed over a 2-year follow-up
measured by DXR-BMD (-0.90%, P < 0.01), but not by DXA-
BMD (0.00%, P = 0.87). DXA-BMD hand bone loss was only
observed in patients with disease duration d3 years and not in
patients with longer disease duration (-0.96% versus 0.24%, P
< 0.01), whereas loss of DXR-BMD was independent of disease
duration. Disease activity (measured by the disease activity
score including 28 joints) independently predicted loss of DXR-
BMD but not changes in the DXA-BMD hand in the multivariate
analysis. The change in DXR metacarpal cortical index was
highly correlated to DXR-BMD (r = 0.94, P < 0.001).
These data suggest that DXR-BMD may be a more appropriate
technique to identify RA-related bone involvement in hands
compared with DXA-BMD measurement, but further studies are
needed to explore this hypothesis.
Introduction
Periarticular bone loss and erosions on radiographs are char-
acteristic features of bone damage in rheumatoid arthritis (RA)
[1], and both features are caused by joint inflammation [2].
Substantial data suggest a common cellular pathway for both
periarticular bone loss and erosions involving the osteoclast
cell [3,4]. In active RA there is an excess production of proin-
flammatory cytokines (for example, IL-1 and TNFD), which
stimulates receptor activator of nuclear factor kB ligand
(RANKL) to activate the osteoclast cell [3-5].
Because periarticular bone loss is an early finding and may
also precede erosions on radiographs [6], quantitative hand
bone measurements that capture periarticular osteoporosis
have been proposed as outcome measures in early RA [7,8].
Inflammation of the joints, however, is not restricted to the
early phase of the RA disease, but may be present during the
entire disease course [9]. Hand bone loss could therefore
potentially be an outcome measure in RA patients with pro-
longed disease.
AOT = antiresorptive osteoporotic treatment; BMD = bone mineral density; DAS 28 = disease activity score including 28 joints; DMARD = disease-
modifying antirheumatic drugs; DXA = dual-energy X-ray absorptiometry; DXR = digital X-ray radiogrammetry; IL = interleukin; MCI = metacarpal cor-
tical index; MHAQ = Modified Health Assessment Questionnaire; RA = rheumatoid arthritis; TNF = tumor necrosis factor.
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Several devices for quantitative bone measurements have
been developed [10] – for example, quantitative computer
tomography, measuring cortical and trabecular bone sepa-
rately; quantitative ultrasound, providing measures that may
reflect bone quality; dual-energy X-ray absorptiometry (DXA),
which measures total cortical and trabecular bone; and digital
X-ray radiogrammetry (DXR), which measures cortical bone
only. DXA is considered the gold standard among bone meas-
urement devices for assessment of bone density at the hip and
the spine. DXA has not, however, been shown to be superior
to other bone measure devices, such as DXR, in the hand [11].
DXR, which is a further development and digitalized version of
the conventional radiogrammetry [12], is a new promising
method for assessment of cortical hand bone loss [13].
The understanding of hand bone loss as an outcome measure
in RA is mainly limited both due to lack of data from longitudi-
nal studies and due to the small number of patients included
in previous studies. Only a few studies have examined associ-
ations between disease factors and hand bone loss in RA, and
most of them have focused on patients with early disease [6-
8,11,14,15]. Data from two longitudinal studies by Deodhar
and colleagues suggest that whole hand DXA bone mineral
density (BMD) loss only takes place in the first 2–3 years of
the RA disease process, which may limit the use of hand DXA-
BMD as an outcome measure in prolonged disease [7,15].
Only a few studies have compared hand DXA-BMD with hand
cortical bone DXR-BMD in RA [11,16].
The aim of the present study was to explore hand bone loss as
a disease outcome measure in established RA assessed by
DXR and by DXA and to compare the two methods.
Materials and methods
Patients
The 215 RA patients (45 males and 170 females) included in
the present study were recruited from a longitudinal cohort of
366 RA patients (aged 20–70 years) [17], all patients fulfilling
the American College of Rheumatology (ACR) criteria and
enrolled in the Oslo RA register [18]. Two-year changes in
generalized bone loss at the hip and the spine from this origi-
nal cohort have previously been described in detail [17]. In the
present study, only patients with hand radiographs and DXA-
BMD measurement of the hand at baseline and 2-year follow-
up were included; 151 patients missed at least one BMD
measurement and were excluded. There were no other exclu-
sion criteria.
Demographic and clinical variables
The demographic and clinical characteristics of the patients
(Table 1) were recorded by a combination of self-reported
questionnaires, interview and clinical investigation, as previ-
ously reported [17]. In short, the clinical examination included
28-swollen and tender joint counts as well as routine labora-
tory tests. The disease activity score including 28 joints
(DAS28) was computed based on the erythrocyte sedimenta-
tion rate [19]. Patients with a titer t64 of the Waaler–Rose
reaction were classified as rheumatoid factor-positive. The
physician's global assessment of disease activity was meas-
ured on a visual analogue scale (0–100 mm). Use of antire-
sorptive osteoporotic treatment (AOT) with bisphosphonates
or hormone replacement therapy, prednisolone and disease-
modifying antirheumatic drugs (DMARD) was recorded. Phys-
ical disability was measured by the Modified Health Assess-
ment Questionnaire (MHAQ) (eight items; range of scores 1–
4) [20].
Bone mineral density measurements
The DXR-BMD and the DXR metacarpal cortical index (MCI)
was measured by the Pronosco X-posure system™ (version
2.0; SECTRA, Linköping, Sweden) [13], a computer version of
the traditional technique of radiogrammetry [12]. The compu-
ter automatically recognizes, on standard radiographs, regions
of interest around the narrowest part of the second, third and
fourth metacarpal bones of the hand. In each region, the corti-
cal thickness, bone width and porosity is measured 118 times
per centimeter. The final BMD estimate is defined as: DXR-
BMD = c × VPAcomb × (1 – p), where c is a constant (deter-
mined such that DXR-BMD on average is equal to the mid-dis-
tal forearm region of the Hologic QDR-2000 device (Hologic
Inc., Bedford, MA, USA)), VPA is the volume per area and p is
the porosity. The DXR method has previously been described
in detail [13,21]. The MCI is defined as the combined cortical
thickness divided by the outer cortical diameter and is a rela-
tive measure independent of bone size or bone length [22,23].
The DXR method has improved the precision of MCI for diag-
nosing cortical bone loss [12,23]. All radiographs of the hand
were acquired by a Siemens Multix Polymat equipment (Sie-
mens AG, Erlangen, Germany) (AGFA Curix film; film focus
distance, 1 m; X-ray tube voltage, 55 kV; exposure dose, 6
mAs).
Standardized BMD measurements for the left and right hands
and the total hip and spine (L2–L4) were performed using the
same DXA equipment (Lunar Expert; Lunar Corporation, Mad-
ison, WI, USA) both at baseline and follow-up. All procedures
were in accordance with the manufacturer's standardized pro-
cedures for hand BMD measurements.
For the DXR-BMD most previous studies have used the non-
dominant hand [11,14], while for DXA measures there is no
consistency and both hands [8], the right hand [15,24] and
the nondominant hand [11] have all been used. To avoid bias
regarding dominant and nondominant hands and to achieve
better precision, we used the mean of both hands. Only
patients who had complete measurements for both DXA-BMD
and DXR-BMD in both hands were therefore included.
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Precision of bone mineral density measurements
Short-time precision was calculated from the material of 28
healthy individuals who underwent duplicate hand BMD meas-
urements and duplicate hand radiographs of both hands with
repositioning of the hand between each assessment. Short-
time precision based on the duplicate measurements,
expressed as the percentage coefficient of variation, was
0.28% for the DXR-BMD hand and was 0.76% for the DXA-
BMD hand. Long-time precision for DXR-BMD based on daily
measurement of one hand radiograph was 0.25%, and long-
time precision for the DXA-BMD hand based on daily meas-
urements of the aluminum spine phantom supported by the
Lunar Expert (Lunar Corporation) was 0.80%
Ethics and legal aspects
The study was approved by the regional committee for ethics
and medical research.
The Norwegian Data Inspectorate approved the registry of RA
patients in Oslo.
Statistical analysis
The statistical analyses were carried out using the SPSS pro-
gram, version 13 (SPSS Inc., Chicago, IL, USA).
Nonparametric tests were used for comparisons between
groups (Mann–Whitney and Kruskal–Wallis tests) and within
groups (Wilcoxon test) because of a skewed distribution of
data. Results are presented as the median and interquartile
range (25th–75th percentiles). Bivariate correlations were
tested using Spearman's correlation.
Bone loss over time was expressed as a negative value.
Changes of BMD measurements were compared across
groups according to the disease duration (cut-off 3 years),
baseline DAS28 (<3.2, low disease activity; 3.2–5.1, moder-
ate disease activity; >5.1, high disease activity) and baseline
MHAQ score (<1.50, 1.50–1 99, t2). The 3-year cut-off value
for disease duration was chosen for pragmatic reasons due to
a low number of included patients with short disease duration
and reports in the literature suggesting hand bone loss only
takes place in the first 3 years of disease duration [7].
Table 1
Patient characteristics at baseline and at 2-year follow-up
Variable n Baseline At 2-year follow-up
Demographic
Age (years) 215 57.4 (49.1–64.7)
Female 215 170 (79.0%)
Menopause 170 111 (65.3%)
Body mass index (kg/m2) 215 23.9 (21.3–26.2) 24.0 (21.5–26.2)
Smoker 210 65 (31.0%) 67 (31.9%)
Disease
Disease duration (years) 215 9 (4–16)
Age at disease onset (years) 215 45.0 (33.0–53.0)
Rheumatoid factor-positive 202 97 (48.0%)
Physician's global assessment score (visual analogue scale, 0–100 mm) 203 19.0 (8.0–39.8) 17.6 (8.5–30.0)
Modified Health Assessment Questionnaire (range 1–4) 214 1.50 (1.13–1.75) 1.50 (1.13–1.87)
Erythrocyte sedimentation rate (mm/hour) 210 16 (9–27) 14 (8–27)
Disease activity score including 28 joints 202 4.04 (3.17–4.96) 4.26 (3.36–5.06)
Medication
Ever user of disease-modifying antirheumatic drugs 213 177 (83.1%) 177 (83.1%)
Corticosteroids 208 79 (37.9%) 85 (40.9%)
User of corticosteroids in the 2-year period 208 93 (44.7%)
Antiresorptive osteoporosis treatment 209 47 (22.5%) 68 (32.5%)
Ever user of antiresorptive osteoporosis treatment 209 92 (44.0%)
Calcium and/or vitamin D 210 113 (53.8%) 155 (73.8%)
Data presented as the median (interquartile range) or as the absolute value (%).
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The predictive values of disease duration, DAS28 and MHAQ
score were also tested in a multiple linear regression model,
with the change of hand BMD as the dependent variable and
with adjustments for age, gender, rheumatoid factor and use
of medication (AOT, prednisolone and DMARD). Enter and
stepwise procedures were used. According to inspection of
Q–Q plots, the distribution of residuals showed acceptable fit
to the normal distribution regarding hand DXR-BMD, whereas
one outlier was identified in the analysis with hand DXA-BMD
as the dependent variable. This analysis was therefore per-
formed both with and without the outlier.
Two tailed P values of 0.05 or less were considered statisti-
cally significant.
Results
Patient characteristics at baseline and at follow-up are pre-
sented in Table 1. The 215 examined patients in this study had
shorter disease duration (9 years versus 15 years, P < 0.01),
lower disease activity measured by the DAS28 (4.00 versus
4.62, P < 0.01), lower global assessment (19 versus 30, P <
0.01) and used less prednisolone (37% versus 54%, P <
0.01) compared with those who were not included (n = 151)
from the original cohort (n = 366). The two groups were similar
regarding age, gender, body mass index, smoking habits, rheu-
matoid factor, age of disease onset, erythrocyte sedimentation
rate, menopause in women and use of DMARD and AOT.
Change in bone mineral density
In the entire group, a significant loss in hand BMD was seen at
2 years as measured by DXR-BMD (-0.90%) and DXR-MCI (-
1.18%), but not as measured in the DXA-BMD hand (0.00%)
(Figure 1). A significant bone loss was also observed for the
DXA-BMD in the total hip (-0.72%) and in the spine L2–L4 (-
0.78%) (Figure 1).
The correlation (r value) between the DXR-BMD hand and the
DXA-BMD hand was 0.88 (P < 0.001) for baseline values and
was 0.35 (P < 0.001) for 2-year BMD changes. Correlations
between the change in the DXA hand and in the DXA total hip
and spine were 0.35 (P < 0.001) and 0.18 (P = 0.01),
whereas correlations between the change in the DXR hand
and DXA total hip and spine were 0.23 (P = 0.001) and 0.10
(P = 0.16), respectively. The DXR-MCI was highly correlated
with the DXR-BMD both at baseline (r = 0.86, P < 0.001) and
as the percentage change over 2 years (r = 0.94, P < 0.001).
Association between disease duration and bone loss
At baseline 37 patients had a disease duration of 3 years or
less and 178 patients had a disease duration longer than 3
years. DXA-BMD hand bone loss was only observed in
patients with disease duration less than 3 years and not in
patients with longer disease duration (-0.96% versus 0.24%,
P < 0.01) (Table 2), whereas loss of DXR-BMD (-0.46%
versus -0.93%, P = 0.76) as well as loss of DXR-MCI (-0.89
versus -1.29, P = 0.66), of the DXA-BMD total hip (-0.26%
versus -0.76%, P = 0.51) and of the DXA-BMD spine (-0.71%
versus -0.82%, P = 0.64) occurred independent of disease
duration. The changes in BMD in the subgroups (according to
disease duration) were all significant except for the DXA-BMD
hand patients with disease duration longer than 3 years (P =
0.26) and the DXA-BMD spine (P = 0.60) and DXA-BMD total
hip patients with disease duration less than 3 years (borderline
significant, P = 0.06).
The patients with short and long disease duration were com-
parable with regard to demographic variables, disease activity
and treatment with DMARD and corticosteroids, but AOT was
used less frequently by patients with short disease duration
than by patients with long disease duration (16.1% versus
35.5%, P = 0.04). The difference in DXA hand bone loss
across patients with short and long disease duration, however,
was also significant in the subgroup not using AOT (-1.41%
Figure 1
Bone loss in 215 rheumatoid arthritis patients followed for 2 years. 
Bone loss assessed by digital X-ray radiogrammetry (DXR) bone min-
eral density (BMD) and metacarpal cortical index (MCI) of the hand, 
and by dual-energy X-ray absorptiometry (DXA) BMD of the hand, total 
hip and spine (L2–L4).
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versus 0.11%, P = 0.02). These findings are consistent in a
linear regression model adjusted for other variables that may
influence hand bone loss (Table 3). The analysis was per-
formed both with and without the outlier, with the same results.
Association between disease activity score and hand 
bone loss
At baseline 55 patients had low disease activity, 103 patients
had moderate disease activity and 44 patients had high dis-
ease activity. Bone loss changes, as measured by DXR-BMD,
differed across patients with different levels of disease activity
(low, -0.29%; moderate, -1.13%; and high, -1.03%; P = 0.03),
and were borderline significant for DXR-MCI (-0.76, -1.34 and
-1.13, P = 0.06) (Table 2). No significant difference in DXA-
measured hand BMD change was found for the low, moderate
and high levels of disease activity (-0.40% versus 0.26% ver-
sus 0.04%, respectively; P = 0.40). Hand BMD baseline val-
ues, however, were significantly lower in the group with high
disease activity in both the DXR-BMD and the DXA-BMD
(Table 2).
Table 2
Comparison of the baseline and the change in hand bone mineral density
Disease duration DAS28 at baseline MHAQ at baseline
d3 years >3 years P value* <3.2 3.2–5.1 >5.1 P value <1.50 1.50–1.99 t2.0 P value
n 37 178 <0.01 55 103 44 <0.01 102 78 34 <0.01
Age (years) 55.4
(43–62)
58.0
(50–65)
0.10 53.5
(39–61)
55.8
(49–64)
62.2
(57–67)
<0.01 53.6
(41–64)
58.9
(52–64)
61.2
(54–67)
<0.01
DXA-BMD 
(g/cm2)
0.39
(0.34–0.43)
0.36
(0.31–0.41)
0.04 0.40
(0.36–0.43)
0.38
(0.32–0.42)
0.33
(0.28–0.38)
<0.01 0.38
(0.33–0.43)
0.37
(0.31–0.41)
0.34
(0.30–0.39)
0.13
DXA-BMD 
change (%)
-0.96
(-4.4 to 1.5)
0.24
(-1.4 to 2.1)
<0.01 -0.40
(-2.4 to 1.8)
0.26
(-1.3 to 2.2)
0.04
(-3.4 to 2.2)
0.40 0.11
(-2.5 to 2.1)
0.0
(-1.2 to 2.0)
-0.12
(-4.1 to 2.2)
0.75
DXR-BMD 
(g/cm2)
0.57
(0.50–0.61)
0.51
(0.44–0.56)
<0.01 0.56 
(0.50–0.61)
0.53
(0.45–0.58)
0.46
(0.38–0.52)
<0.01 0.54
(0.49–0.59)
0.49
(0.44–0.57)
0.50
(0.40–0.53)
<0.01
DXR-BMD 
change (%)
-0.46
(-3.6 to 0.2)
-0.93
(-2.8 to 0.3)
0.76 -0.29
(-1.6 to 0.7)
-1.13
(-3.2 to 0.1)
-1.03
(-4.3 to 0.5)
0.03 -0.80
(-2.6 to 0.1)
-0.94
(-2.8 to 0.5)
-0.81
(-3.7 to 0.5)
0.90
DXR-MCI 0.40
(0.37–0.49)
0.37
(0.31–0.45)
<0.01 0.41
(0.34–0.48)
0.39
(0.33–0.46)
0.32
(0.27–0.38)
<0.01 0.40
(0.33–0.48)
0.37
(0.31–0.43)
0.33
(0.29–0.41)
<0.01
DXR-MCI 
change (%)
-0.89
(-5.5 to 0.0)
-1.29
(-3.1 to -0.1)
0.66 -0.76
(-1.8 to 0.3)
-1.34
(-3.4 to -0.4)
-1.13
(-5.2 to -0.2)
0.06 -1.33
(-3.1 to -0.3)
-1.20
(-3.2 to 0.3)
-0.71
(-5.0 to 0.0)
0.74
Digital X-ray radiogrammetry (DXR) bone mineral density (BMD), DXR metacarpal cortical index (MCI) and dual-energy X-ray absorptiometry (DXA) BMD assessed for 
levels of disease duration, for disease activity (disease activity score including 28 joints (DAS28)) and for physical function (Modified Health Assessment Questionnaire 
(MHAQ)) in rheumatoid arthritis patients. Data presented as the medians (interquartile range). *P values between subgroups.
Table 3
Risk factors for hand bone loss in a multivariate linear regression model
DXA-BMD hand percentage change DXR-BMD hand percentage change DXR-MCI percentage change
B (standard error) P value B (standard error) P value B (standard error) P value
Disease activity score including 28 
joints
0.09 (0.25) 0.73 -0.47 (0.16) 0.003 -0.47 (0.18) 0.009
Disease duration <3 years -2.84 (0.88) 0.001 0.46 (0.55) 0.40 0.45 (0.63) 0.47
Baseline BMD (g/cm2)/MCI -9.70 (5.01) 0.05 -3.80 (2.51) 0.13 -5.79 (2.81) 0.04
Prednisolone during 2-year follow-
up (no/yes)
0.44 (0.69) 0.53 -0.03 (0.43) 0.95 -0.41 (0.49) 0.40
Ever disease-modifying 
antirheumatic drug user (no/yes)
-0.31 (0.90) 0.73 -0.58 (0.55) 0.30 -0.56 (0.63) 0.38
Ever antiresorptive osteoporosis 
treatment user (no/yes)
0.78 (0.70) 0.27 0.03 (0.42) 0.95 -0.05 (0.47) 0.91
R2 0.11 0.05 0.06
B values are unstandardized coefficients. Age, gender, rheumatoid factor and the Modified Health Questionnaire were also tested, but did not 
influence the results. DXA, dual-energy X-ray absorptiometry; DXR, digital X-ray radiogrammetry; BMD, bone mineral density; MCI, metacarpal 
cortical index.
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The correlation (r value) between the DAS28 at baseline (con-
tinuous scale) and the hand DXR-BMD change was -0.19 (P
= 0.01), between the DAS28 and the DXR-MCI change was -
0.16 (P = 0.03), and between the DAS28 and the hand DXA-
BMD change was 0.08 (P = 0.27). Patients in the group with
high disease activity were significant older than the group with
lowest disease activity. In a multivariate model, however, dis-
ease activity was independently associated with the percent-
age change in DXR-BMD (B = -0.47, P < 0.01) (Table 3) and
with the DXR-MCI (B = -0.47, P < 0.01), after adjusting for
other variables that could influence hand bone change as well
as age.
Association between functional disability (MHAQ score) 
and hand bone loss
At baseline, 102 patients had a MHAQ score less than 1.50,
78 patients a score between 1.50 and 1.99, and 34 patients
had a MHAQ score of two or more. The patient with highest
MHAQ score was older than patients with lower MHAQ
scores. Regarding correlation between the MHAQ score at
baseline and the change in hand DXR-BMD, the DXR-MCI
hand and the DXA-BMD hand were nonsignificant both for
continuous values (r = 0.00, P = 0.96; r = 0.03, P = 0.70; and
r = -0.05, P = 0.51) and for groups (r = 0.02, P = 0.82; r =
0.05, P = 0.47; and r = -0.02, P = 0.82) for the MHAQ score
ranges <1.5, 1.50–1.99 and t2, respectively. There were no
differences in the change in hand BMD dependent on the
MHAQ group either in the DXR-BMD hand, the DXR-MCI
hand or the DXA-BMD hand. Baseline values, however, were
significantly higher in the group with the lowest MHAQ score
with regards to DXR-BMD and DXR-MCI (Table 2). No such
findings were seen regarding DXA measurements.
Associations between treatment and hand bone loss
At follow-up 33% of the patients were current users of AOT
(88% used hormone replacement therapy and 12% used
bisphosphonates) and 44% were ever users. A significant dif-
ference in DXA-BMD hand change was found between users
and nonusers of AOT (0.44% versus 0%, P = 0.04). No such
difference was seen for DXR-BMD (-1.01% versus -0.66%, P
= 0.54) or DXR-MCI (-1.14 versus -1.19, P = 0.60) in users
versus nonusers of AOT. Use of AOT, however, was not sig-
nificantly associated with the change in DXA-BMD in the mul-
tivariate analyses (Table 3).
No significant difference in hand bone change was seen
between ever users (83%) and never users (17%) of DMARD
regarding the DXR-BMD hand (-0.90% versus -0.85%, P =
0.29), the DXR-MCI hand (-1.19 versus -0.78, P = 0.17) or the
DXA-BMD hand (0.27% versus -0.34%, P = 0.22). During the
2-year follow-up 45% of patients had used prednisolone and
41% were current users at follow-up with a mean dose of 5.7
mg. No significant difference in change of hand BMD was
observed between users and nonusers of prednisolone
regarding DXR-BMD (-0.94% versus -0.66%, P = 0.19) or
DXA-BMD (0.62% versus 0%, P = 0.17), but a group
difference between users and nonusers was observed for
DXR-MCI (-1.42 versus -0.98, P = 0.05). Prednisolone users,
however, had a significantly higher disease activity than non-
users (data not shown) and the significant association
between prednisolone and the change in DXR-MCI disap-
peared in the multivariate analysis (Table 3).
Discussion
The present study had two main findings. First, total hand bone
loss measured by DXA-BMD seems to occur only in the first
years of RA disease, whereas DXR-BMD-measured cortical
hand bone loss occurs both in early stages as well as late
stages of the disease. Second, patients with high disease
activity at baseline lost more DXR-BMD and DXR-MCI than
patients with low disease activity. In the present study there
were only marginally differences between DXR-BMD and
DXR-MCI, and our main focus in the discussion will therefore
be on DXR-BMD.
A discrepancy in loss of DXA-BMD hand between early dis-
ease and long-standing disease has previously been sug-
gested based on the results of two longitudinal studies [7,15].
Hand bone loss was only observed in the first 3 years and then
stabilized over the next 2 years in a longitudinal study of 29
patients with RA [7]. Degenerative bone changes and
increased inflammation in the small joints of the hand in the
first years of the disease has been suggested partly to explain
this finding [25]. As DXA-BMD measures both trabecular and
cortical bone, a third explanation could be that the rate of
trabecular and cortical bone loss is different in early stages
versus late stages of the disease. Even if DXR-BMD hand
bone loss occurs during the whole RA disease course, the
bone loss has been shown to be more rapid in early disease
compared with more prolonged disease [14]. Böttcher and
colleagues reported annual DXR-BMD loss in the first 6 years
of the disease to be as high as 11%, with a subsequent
decline to 3–4% over the next years [14].
Interestingly, changes in the DXA-BMD in the total hip and
spine were independent of the disease duration. There are few
studies that have compared periarticular and generalized oste-
oporosis among RA patients [8,26-28]. Hand bone loss in
early RA has been shown to occur more rapidly than bone loss
in the hip and the spine [8,28]. Radiographic joint damage has
been shown to be more strongly correlated with low hand
DXR-BMD than DXA-BMD at the hip and the spine [26,27]. In
a randomized, placebo-controlled trial among early RA
patients, use of prednisolone reduced hand bone loss [29].
These data suggest that the effect of inflammation on hand
bone in RA may be greater than the effect on other bones (for
example, spine and hip). The generalized bone loss may be
more associated with the prolonged course of RA, including
the use of corticosteroids and immobility [30].
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The other main finding in the present study is that patients with
high disease activity at baseline lost more DXR-BMD than
patients with low disease activity. Surprisingly, this association
was not found between DXA-BMD hand bone loss and base-
line disease activity, and this lack of association was consist-
ent in both patients with short and long disease durations
(data not shown). Some previous studies in early RA, however,
have shown that disease activity is associated with both DXA-
BMD-measured generalized bone loss [31] as well as local-
ized bone loss [8]. Gough and colleagues [31] found that early
RA patients with active disease (defined as mean C-reactive
protein >20 mg/l over 12 months) showed greater generalized
bone loss at the hip and the spine compared with patients with
lower disease activity. Haugeberg and coworkers [8] found
that C-reactive protein independently predicted hand BMD
loss in patients with early undifferentiated arthritis who, during
a 12-month follow-up, developed RA. Explanations for contra-
dictory findings between these two studies and our study may
be differences in disease activity and disease duration in the
examined study cohorts.
The association between disease activity and DXR-BMD hand
bone loss in our study was shown when dichotomizing the
patients into groups based on disease activity (Table 2) and in
linear multivariate analyses (Table 3). These consistent associ-
ations combined with the demonstration of bone loss inde-
pendent of disease duration (Table 3) suggest that DXR-BMD
is a robust outcome measure in RA, reflecting the inflammatory
disease process in early stages as well as late stages of the
disease. Only a few previous studies have been carried out
with DXR-BMD loss as the key outcome measure [11,32].
Jensen and colleagues [11] found in patients with early RA
(<2 years) that DXR-BMD was more strongly associated with
disease activity than hand DXA-BMD. In a cross-sectional
study, Böttcher and colleagues found that DXR-BMD was
negatively correlated with disease activity measured by the
DAS28 [32].
In the present study the hand bone loss measured by both
DXR-BMD and DXA-BMD was less than that reported by
other workers. Jensen and colleagues [11] found a loss of
DXR-BMD of 5% over 2 years in an early RA disease group,
and Haugeberg and colleagues found that the DXA-BMD
hand loss was reduced by 4.3% in early RA disease patients
[8]. One explanation for the lower rate of hand bone loss in the
present study may be that our cohort was obtained from an
observational study of patients with different levels of disease
activity and duration. The recruitment of these patients from a
validated RA register is also a strength of the present study as
the results provide insight into what takes place in the real
world of RA patients regarding hand bone loss [18]. Another
reason for the less bone loss may be that the DXA-BMD hand
was assessed as a whole hand and not around selected finger
joints, which according to the cross-sectional study by Alen-
feld and colleagues [33] has been suggested to be the best
site to capture periarticular bone loss in RA. There are disad-
vantages using periarticular regions compared with the whole
hand, however, which include poorer precision and poorer fea-
sibility [33]. Because of skewed data, median values were
used instead of mean values, neutralizing the effect of
extremes on the BMD results.
The limitations of the present study were that relatively few
patients had short disease duration. The effect of medication
on the bone was also difficult to evaluate because patients had
no standardized treatment but were treated according to clin-
ical judgment. Adjusting for medication use in the multivariate
analyses had no significant effect on BMD change either on
the DXR-BMD hand or the DXA-BMD hand. A study with a ran-
domized controlled design would give stronger evidence for
the effects of medication.
Onepotential limitation using quantitative bone measures as
an outcome measure in RA is the influence of normal bone
loss, which also takes place in healthy adult subjects. Normal
bone loss for DXR-BMD has only been examined in cross-sec-
tional studies reporting an annual rate of bone loss between
0.4% and 0.9% [22,34-36]. For DXA-BMD hip and spine
bone loss, using cross-sectional data has been shown to over-
estimate the rate ofnormal bone loss compared with longitudi-
nal studies [37]. In the multivariate model, however, age was
not a significant predictor for hand bone loss over 2 years
either for DXR-BMD or for DXA-BMD (data not shown).
Conclusion
We suggest that hand DXA-BMD can only be used as an out-
come measure in RA in the first years of the disease, whereas
DXR-BMD may be used as a marker for disease activity and
bone loss during the whole disease process, both in early dis-
ease as well as prolonged disease. The reason for this dis-
crepancy is not clear and additional studies are warranted to
further explore this hypothesis.
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ABSTRACT
Objective: To examine 1-year hand bone loss in early
rheumatoid arthritis (RA) as a predictor of radiographic
damage at 5-year and 10-year follow-up
Methods: A total of 136 patients with RA (disease
duration 0–4 years) were followed for 10 years with
clinical data and hand radiographs. Joint damage was
scored according to the van der Heijde modification of the
Sharp method (vdH Sharp score) and hand bone mineral
density (BMD) was measured by digital x ray radio-
grammetry (DXR). Group comparisons, correlation ana-
lyses and multivariate analyses were performed to
evaluate the relationship between hand bone loss and
radiographic joint damage.
Results: Patients with hand BMD loss at 1 year had a
higher median increase in vdH Sharp score compared to
patients without loss at 5 years (12 vs 2, p= 0.001) and
10 years (22 vs 4, p= 0.002). In a linear regression
model adjusting for age, gender, baseline C-reactive
protein (CRP), anti-cyclic citrullinated peptide (CCP), IgM
rheumatoid factor (RF) and radiographic damage, absolute
hand DXR-BMD loss at 1 year was an independent
predictor of radiographic outcome at 5 years (p,0.01)
and 10 years (p= 0.02). In a logistic regression model
the odds ratio (95% CI) for radiographic progression
among patients with hand BMD loss was 3.5 (1.4 to 8.8)
and 3.5 (1.4 to 8.4) at 5 and 10 years, respectively.
Conclusion: Early hand bone loss measured by DXR-
BMD is an independent predictor of subsequent radio-
graphic damage. Our findings support that quantitative
hand bone loss in RA precedes radiographic joint damage
and may be used as a tool for assessment of bone
involvement in RA.
Periarticular osteoporosis and joint erosion are
both known as radiographic hallmarks of rheuma-
toid arthritis (RA).1 Evidence from animal2 3 and
human studies4 support that erosions and osteo-
porosis are caused by an increased activation of
osteoclasts. Hand bone loss has been shown to take
place in early RA,5 even in the undifferentiated
stage of the RA disease process.6 7 On hand
radiographs periarticular osteoporosis has been
shown to precede the development of erosions.8
Measures of quantitative hand bone loss eg, by
dual energy x ray (DXA) and digital x ray radio-
grammetry (DXR) in early RA have been proposed
as an outcome measure for bone involvement.9–11
However, there is a lack of data on the relationship
between hand bone loss and radiographic joint
damage. Cross-sectional studies have shown a
moderate correlation between low hand bone
mineral density (BMD) and radiographic
damage10 12–17 and two small longitudinal studies
have indicated that early hand bone loss may
predict subsequent radiographic joint damage.18 19
Thus, the objective of this study was to examine
if cortical hand bone loss in early RA, as assessed by
DXR in the first year of follow-up, could predict
radiographic joint damage at 5-year and 10-year
follow-up.
MATERIALS AND METHODS
Study design and study population
The current analysis is a part of the European
Research on Incapacitating Disease and Social
Support (EURIDISS) longitudinal observational
study. The patients and methods have previously
been described in detail elsewhere.20 21 In short, all
patients had disease duration of maximum 4 years
at inclusion, were aged 20–70 years and fulfilled
the American College of Rheumatology (ACR)
criteria for RA.1 Clinical, laboratory and radio-
graphic data were collected at baseline and at 1, 2,
5 and 10 years. During the observation period,
patients were treated according to clinical judge-
ment by their rheumatologist. Sera from the
baseline visit were stored at 270 degrees for later
analysis of micro-C-reactive protein (CRP) (Dade
Behring, Newark, New Jersey, USA), anti-cyclic
citrullinated peptide (CCP) (ELISA, Inova
Diagnostics, San Diego, California, USA) and
rheumatoid factor IgM (IgM RF) (in-house ELISA).22
Patients with hand radiographs at baseline,
1-year follow-up and either 5-year or 10-year
follow-up were included in the present analyses.
The number of patients with baseline radiographs
available for scoring were 163, and 15 of these
were excluded due to missing radiographs at 5 and
10 years. Of the remaining 148 patients, baseline
radiographs from 5 patients could not be analysed
for DXR-BMD because the radiographs were
underexposed and 7 patients were excluded at
the 1-year follow-up (5 radiographs were missing,
1 was underexposed and 1 patient had surgical
material in the metacarpal bone). A total of 136
patients were included in the final analyses.
Missing radiographic scores at 5 years (n=11)
were replaced by a projected score based on the
radiographic progression from baseline to the 10-
year assessment (horizontal imputation). Any 10-
year missing data (n=18) were replaced by last
observation carried forward23 to avoid overestima-
tion of the radiographic damage. Missing DXR-
BMD values were not imputed. To test the
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robustness of the results, all analyses were repeated without
imputation.
Radiographic analyses
The radiographs were scored according to the van der Heijde
modification of the Sharp score (vdH Sharp score),24 and were
read in known time order by one experienced reader.21 In all, 16
joint areas for erosions (0–5) and 15 for joint space narrowing
(JSN) (0–4) were evaluated in each hand, and the maximum
score was 280. Conventional radiographs were available at
baseline, 1, 2 and 5 years, while radiographs at 10 years were
digitised. Scoring of digitised and conventional radiographs have
been shown to yield similar results.25
Analyses were performed for continuous and dichotomised
data. Cut-off for an important increase in vdH Sharp score was
defined as an increase of 1 unit per year (ie, 5 units at the 5-year
and 10 units at the 10-year follow-up assessment).22 The
smallest detectable change (SDC) in radiographs read in known
time order has been found to be 2.9 units.26 The conventional
radiographs were acquired by a Siemens Multix Polymat
equipment (film: AGFA Curix (AGFA, Mortsel, Belgium); film
focus distance (FFD): 100 cm; x ray tube voltage: 55 kV;
exposure dose: 6 mAs). The digital radiographs were acquired
by an AGFA ADC Compact (computed radiography) and a
Siemens (Erlangen, Germany) tube (AGFA ADCCHR image plate,
x ray tube voltage 50 kV, FFD 100 cm, exposure dose 5 mAs).
Cortical hand bone density
The conventional hand radiographs used for radiographic
scoring of joint damage was also used for hand BMD measures
at 1, 2 and 5 years. Cortical hand BMD was measured by DXR
Pronosco X-posure system, V. 2.0 (Sectra, Linko¨ping, Sweden),27
which is a development of the traditional technique of radio-
grammetry.28 On hand radiographs the computer automatically
recognises regions of interest around the narrowest part of the
second, third and fourth metacarpal bone. In each region,
cortical thickness, bone width and porosity is measured 118
times per cm. The BMD estimate is defined as: BMD-
DXR=c6VPAcomb6(1–p), were c is a constant (empirically
determined so DXR-BMD on average was equal to the mid-
distal forearm region of the Hologic QDR-2000 densitometer;
Hologic, Bedford, Massachusetts, USA); VPA is volume per area
and p is porosity. This method has been described in detail
elsewhere.27 29
Precision was calculated from 28 healthy individuals who
underwent duplicate hand radiographs with repositioning of the
hand between each measure. The coefficient of variation (CV%)
was found to be 0.28%, and least significant change (LSC) was
0.78%30
The LSC was used as cut-off to define a DXR-BMD loss
exceeding the measurement error on the individual level. We
applied the mean values of both hands to avoid bias regarding
dominant and non-dominant hand, and this approach has been
shown to improve precision.19
Statistics
The statistical analyses were performed using SPSS V.14 (SPSS,
Chicago, Illinois, USA).
Because of skewed data, non-parametric tests were used.
Hand BMD loss was tested as a continuous and a dichotomised
variable. The following methods were used: Spearman correla-
tion, group comparisons using the Mann–Whitney U test and
multivariate analyses (linear and logistic regression analyses).
A linear regression model was developed to investigate if
absolute hand BMD loss during the first year could predict
subsequent radiographic outcome (dependent variable). The
model was adjusted for age and gender as well as for other
potential predictors of radiographic damage: anti-CCP (cut-off:
25 U/ml), IgM RF (cut-off: 25 U/ml), CRP, Health Assessment
Questionnaire (HAQ) and baseline vdH Sharp score. Separate
models for 5 and 10 years were developed.
In a logistic regression model patients were dichotomised as
progressors and non-progressors of radiographic damage with an
annual increase of 1 unit as cut-off value (dependent variable)
and stratified into patients with and without DXR-BMD loss
with LSC as the cut-off value (independent variable). This
Table 1 Baseline characteristics in 136 included patients with
rheumatoid arthritis (RA) and the 102 non-participants (mean (SD) values
for continuous variables (also median and range for vdH Sharp score and
DXR-BMD), percentages for counts)
Patients included in
study (n= 136)
Patients not included in
study (n= 102)*
Age (years) 51.3 (12.1) 52.8 (14.2)
Female 76 71
Positive anti-CCP 62 59
Positive IgM RF 48 48
Disease duration (years) 2.2 (1.2) 2.4 (1.1)
CRP (mg/litre) 9.4 (12.2) 11.0 (13.4)
ESR (mm/h) 26.2 (20.9) 25.5 (18.3)
HAQ score (scale 0–3) 0.9 (0.6) 1.0 (0.7)
Current users of corticosteroids 26 29
Current users of DMARDs 54 49
vdH Sharp score 6.8 (12.2) NA
2.0 (0–69.0)
Hand DXR-BMD (g/cm2) 0.55 (0.09) NA
0.55 (0.33–0.77)
*All group comparisons p.0.05.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-modifying
antirheumatic drug; DXR-BMD, digital x ray radiogrammetry bone mineral density;
ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NA, not
available; RF, rheumatoid factor; vdH Sharp, van der Heijde modification of the Sharp
score.
Figure 1 Cumulative probability plot of digital x ray radiogrammetry
bone mineral density (DXR-BMD) percentage change at 1-year, 2-year
and 5-year follow-up in patients with rheumatoid arthritis (RA).
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model was adjusted for the variables that were statistically
significant in the linear regression model together with age and
gender. For CRP, we used a cut-off of 10 mg/litre. From the
logistic regression model a probability score was calculated to
assess the risk of radiographic progression dependent on the
combination of hand BMD loss, early radiographic damage and
anti-CCP. All tests were two-sided and conducted at the
p=0.05 significance level.
Ethics and legal aspects
The study was approved by the regional committee for ethics
and medical research and data collection was approved by the
Data Inspectorate.
RESULTS
Patient characteristics at baseline are shown in table 1. No
significant differences were observed between the 136 examined
patients in the present analyses and the 102 patients who were
excluded. At 5 years none of the patients were using anti-
tumour necrosis factor (TNF)a therapy and 55% were using
disease-modifying antirheumatic drugs (DMARDs); at 10-year
follow-up the corresponding figures were 12% and 50%,
respectively.
BMD change and radiographic damage
The median loss in hand DXR-BMD expressed in absolute
values (g/cm2) were 0.009 after 1 year, 0.016 after 2 years and
0.031 after 5 years. The percentage changes of hand DXR-BMD
are displayed as a cumulative probability plot in fig 1. The hand
bone change was similar in males and females (data not shown).
The mean (median) change in the vdH Sharp score were 3.6
(1.0), 7.1 (3.0), 15.5 (10.0) and 26.4 (16.0) units after 1, 2, 5 and
10 years, respectively. The correlation coefficient (r) between
change in DXR-BMD and vdH Sharp score increased from
20.35 (p,0.01) at the first year, to 20.47 (p,0.01) at the
second year and 20.56 (p,0.01) at the fifth year.
On the individual level, 67% of the patients had a hand BMD
loss exceeding LSC in the first year of follow-up. The
proportions of patients with radiographic progression in the
hands (defined as 1 unit per year) were 46% after 1 year and
60% after 5 and 10 years. The radiographic progression (median
values) was significantly higher in patients who lost DXR-BMD
vs patients who did not lose DXR-BMD at 5 (12 vs 2, p=0.001)
and 10 years (22 vs 4 p=0.002). These results are shown as
cumulative probability plots in fig 2.
Multivariate linear regression models
Change at 1 year in DXR-BMD was a significant and
independent predictor of vdH Sharp score at 5 and 10 years,
adjusting for other relevant factors as baseline vdH Sharp score,
anti-CCP, IgM RF, baseline micro-CRP, HAQ-score, age and
gender (table 2). In this model a loss of 0.1 g/cm2 would on
average give an increase in vdH Sharp score of 20 units after
5 years and 28 units after 10 years (B values, not shown). Other
significant predictors of radiographic damage were anti-CCP,
radiographic damage at baseline and inflammatory activity
assessed by CRP (the latter only at 5 years) (table 2).
Multivariate logistic regression models
Logistic regression models were created to see whether DXR-
BMD loss could be used as a predictor in a clinical situation. The
models were adjusted for the baseline variables that turned out
to be statistically significant in the linear regression model, ie,
baseline vdH Sharp score (cut-off 1 unit), anti-CCP (cut-off
25 U/ml) and CRP (cut-off 10 mg/litre) together with age and
gender.
Loss of hand DXR-BMD exceeding the LSC during the first
year of follow-up was an independent risk factor for radio-
graphic progression at 5 and 10 years with an odds ratio (95%
CI) of 3.5 (1.4 to 8.8) and 3.5 (1.4 to 8.4), respectively (table 3).
Radiographic damage at baseline and positive anti-CCP were
also significant risk factors for subsequent radiographic damage
(table 3). For these three predictors the probability for
radiographic damage was calculated based on the odds ratios
(OR). The probability of developing radiographic progression
(for 5 years) was calculated as follows: log (p/1–p)=21.61
(constant)+1.26 DXR-BMD loss+1.60 Radiographic damage at
baseline+1.44 anti-CCP positive, where p is the probability and
each variable is entered as a categorical variable (0 or 1)
weighted by the importance of each variable. From this
Figure 2 Change in van der Heijde Sharp score at 5 years (A) and 10
years (B) in patients with rheumatoid arthritis stratified for hand bone
mineral density (BMD) loss at 1 year (cut-off .least significant change
(LSC)). Presented as a cumulative probability plot were each symbol
represent a patient (hand BMD loss n=91, no hand BMD loss n=45).
(A) 5-year change in vdH Sharp score dependent on DXR-BMD loss
or not at 1 year. p= 0.001 (group comparison Mann–Whitney U).
(B) 10-year change in vdH Sharp score dependent on DXR-BMD loss or
not at 1 year. p= 0.002 (group comparison Mann–Whitney U).
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algorithm the probability of radiographic damage at 5 years
could be calculated as 94% for patients with bone loss,
radiographic damage and positive anti-CCP and as 17% for a
patient with none of these risk factors. These results, together
with the 10-year data are depicted in fig 3. For the 5-year and
10-year data, hand bone loss adds additional information to the
subsequent risk for radiographic damage.
Robustness
The multivariate models were also tested without imputation
of missing values. The number of available patients at 5-year
and 10-year follow-up was 126 and 118, respectively. In the
linear regression model a loss of 0.1 g/cm2 DXR-BMD would
give an increase in vdH Sharp score of 19.8 units (p=0.01) at 5
years and 23.2 units (p=0.07) at 10 years. In the logistic
regression model the OR (95% CI) for radiographic damage
among those with hand bone loss were 3.0 (1.2 to 7.7) at 5 years
and 2.9 (1.1 to 7.4) at 10 years. All group comparisons and
correlation analyses remained statistically significant.
DISCUSSION
This study shows for the first time that hand bone loss is an
independent predictor of progression of radiographic joint
damage and that the predictive power is comparable to
biomarkers that are well known predictors of radiographic joint
damage as anti-CCP and CRP.
Algorithms have been proposed to identify patients with poor
prognosis by the presence of various predictors.22 31 32 Up to now
early hand bone loss as a risk factor has not been included in any
of these algorithms. The two characteristics of the DXR-BMD
method, high sensitivity to change29 and ability to predict joint
damage, suggest that hand DXR-BMD may be used in
prediction models of poor outcome in patients with early RA.
In the multivariate analysis and in our algorithm based on
presence or absence of the three risk factors, anti-CCP, erosive
disease at baseline and 1-year change in bone loss, we showed
that hand DXR-BMD gives additionally information to the
other risk factors for predicting radiographic progression.
As illustrated in fig 3, a patient with radiographic damage at
baseline, but negative anti-CCP and no hand bone loss during
the first year will have a 34% probability of an important
radiographic progression after 10 years, whereas a patient with
erosions and hand BMD loss has a probability of 64%. With
additional presence of anti-CCP this probability increases to
87% after 10 years. DXR-BMD has most additional predictive
value in patients with only one risk factor (either baseline
radiographic damage or anti-CCP). These data illustrate the
potential of DXR-BMD as a predictive tool, but we find it
important to recommend that our results also should be
confirmed in patients with very early RA (ie, in patients
without radiographic erosions).
The fact that bone loss in early RA occurs more rapidly than
the development of erosions is not only supported by the
Table 2 Digital x ray radiogrammetry bone mineral density (DXR-BMD) as a predictor of subsequent
radiographic damage in patients with rheumatoid arthristis (RA) at 5-year and 10-year follow-up tested in
multivariate linear regression models (n= 136)
Variable
Radiographic outcome at 5 years (vdH
Sharp score)
Radiographic outcome at 10 years (vdH
Sharp score)
b p Value b p Value
Hand DXR-BMD change at 1 year (g/cm2) 20.15 0.005 20.15 0.02
Baseline vdH Sharp score 0.68 ,0.001 0.56 ,0.001
Positive anti-CCP 0.14 0.02 0.17 0.02
Positive IgM RF 0.09 0.11 0.09 0.17
CRP 0.15 0.005 0.11 0.09
HAQ 20.05 0.30 20.10 0.11
Age (years) 20.08 0.11 20.06 0.36
Female gender 0.02 0.75 0.07 0.25
R2, adjusted 0.69 0.53
Use of disease-modifying antirheumatic drugs and/or corticosteroids at baseline did not influence the model.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; vdH
Sharp, van der Heijde modification of the Sharp score.
Table 3 Digital x ray radiogrammetry bone mineral density (DXR-BMD) as a predictor for subsequent
increase in vdH Sharp score in patients with rheumatoid arthritis (RA) at 5-year and 10-year follow-up in
multivariate logistic regression models
Logistic regression analyses
Increase >5 units at 5 years Increase >10 units at 10 years
b Odds ratio (95% CI) b Odds ratio (95% CI)
DXR-BMD loss.LSC at 1 year 1.26 3.52 (1.42 to 8.75) 1.24 3.46 (1.43 to 8.35)
Baseline vdH Sharp score >1 1.60 4.94 (2.01 to 12.10) 1.45 4.27 (1.78 to 10.27)
Positive anti-CCP 1.44 4.20 (1.77 to 9.98) 1.28 3.59 (1.54 to 8.38)
Elevated CRP (cut-off 10) 0.98 2.66 (0.92 to 7.72) 0.45 1.57 (0.59 to 4.19)
Age 20.02 0.98 (0.94 to 1.02) 20.01 0.99 (0.95 to 1.03)
Female gender 0.34 1.41 (0.52 to 3.86) 0.84 2.32 (0.88 to 6.10)
Constant 21.61 22.11
Goodness of fit (Nagelkerke R
square)
0.44 0.39
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; vdH Sharp, van der Heijde modification of the Sharp score.
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multivariate analysis but also from correlation analysis. The
correlation coefficient between hand bone change and radio-
graphic damage increased from 20.35 at the first year to 20.56
at the fifth year. However it is important to emphasise that
erosions are pathognomonic for bone involvement in RA, while
bone loss may also occur in normal individuals. This limitation
may, however, be a minor problem in studies with short
observation time.19 DXR-BMD values for the 10-year follow-up
are not presented for methodological reasons as these radio-
graphs were digitised and DXR-BMD assessed from digital
printouts has been shown to have a poorer precision than
conventional radiographs.33 Further, the precision regarding
direct analysing of digitised DXR-BMD has not been fully
investigated.
One limitation of this study is that data on generalised bone
loss was not available. From the literature we know that
generalised bone loss has also been found to be associated with
disease activity34 and radiographic damage.35 36 Few studies have
compared periarticular and generalised osteoporosis among
patients with RA.7 13 17 37 Hand bone loss in early RA has been
shown to occur more rapidly than bone loss in hip and spine.7 37
Radiographic joint damage has been shown to be more strongly
correlated with low hand DXR-BMD than DXA-BMD at hip
and spine.13 17 In a randomised placebo controlled trial among
patients with early RA, use of prednisolone reduced hand bone
loss.38 These studies suggest that the effect of inflammation on
hand bone in RA may be greater than the effect on other bones
(eg, spine and hip). In addition the precision of BMD hand, and
particularly DXR-BMD, is better than the precision of DXA
measurements of the hip and spine. This difference also
indicates that a longer observation period may be required to
detect a true loss of bone in hip and spine.19 29
This study examined the relation between early hand bone
loss and radiographic progression at 5 and 10 years. Horizontal
imputations were used for the missing 5-year data and last
observation carried forward used for the missing 10-year data.
This approach was chosen because the literature is not
consistent as to whether radiographic damage increases in a
linear fashion during the first year of the disease and declines
afterwards,39 or increases linearly over a period of 10 years.40 41
By using this conservative imputation the radiographic damage
was not overestimated. No imputations regarding DXR-BMD
were performed. All analyses were also repeated without
imputations and hand bone loss turned out to be a significant
predictor of radiographic outcome in all analyses except for the
linear regression model at 10 years, which showed a borderline
significance.
Although DXR-BMD shows convincing result as a predictor
for radiographic damage, there are a few patients with no DXR-
BMD bone loss who have a high increase in radiographic
damage (fig 2). The reason for this is not clear. One explanation
may be that RA is a heterogenic disease. However, this
emphasise the importance of further research on predictors for
radiographic damage.
In conclusion, we have shown that hand bone loss measured
by DXR-BMD is an independent predictor of subsequent
radiographic damage in patients with RA. Our findings support
that quantitative hand bone measures may be a complimentary
approach in the study of changes in bone involvement in RA
and may be an important tool in the daily clinical work together
with anti-CCP, markers of inflammation and radiographs to
identify patients at high risk of developing progression in
radiographic joint damage.
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ABSTRACT
Objective: The effect of adalimumab on hand osteo-
porosis was examined and related to radiographic joint
damage in the three treatment arms of the PREMIER
study: adalimumab plus methotrexate, adalimumab and
methotrexate monotherapy. Predictors of hand bone loss
were also searched for.
Methods: 768 patients (537 fulfilled 2 years) with
rheumatoid arthritis (RA) for less than 3 years, never
treated with methotrexate, were included. Hand bone loss
was assessed by digital x ray radiogrammetry (DXR) on
the same hand radiographs scored with modified Sharp
score at baseline, 26, 52 and 104 weeks. For DXR,
metacarpal cortical index (MCI) was the primary bone
measure.
Results: At all time points the rate of percentage DXR–
MCI loss was lowest in the combination group (21.15;
22.16; 23.03) and greatest in the methotrexate
monotherapy group (21.42; 22.87; 24.62), with figures
in between for the adalimumab monotherapy group
(21.33; 22.45; 24.03). Significant differences between
the combination group and the methotrexate group were
seen at 52 (p= 0.009) and 104 weeks (p,0.001). The
order of hand bone loss across the three treatment arms
was similar to the order of radiographic progression. Older
age, elevated C-reactive protein and non-use of adali-
mumab were predictors of hand bone loss.
Conclusion: This study supports a similar pathogenic
mechanism for hand bone loss and erosions in RA. The
combination of adalimumab and methotrexate seems to
arrest hand bone loss less effectively than radiographic
joint damage. Quantitative measures of osteoporosis may
thus be a more sensitive tool for assessment of
inflammatory bone involvement in RA.
In rheumatoid arthritis (RA), bone damage on
radiographs presents not only as erosions but also
as periarticular osteoporosis.1 Hand bone loss in
early RA has been shown to occur more rapidly
than bone loss at the hip and spine2–4 and also
predicts radiographic joint damage.5
Inflammatory activation of the osteoclast is
involved in both features. Studies support that
cytokines, eg, tumour necrosis factor (TNF) alpha,
macrophage colony-stimulating factor and receptor
activator of nuclear factor kappa ligand (RANKL),
activate the osteoclast that causes osteoporosis
(localised and generalised) and erosions.6–8
Anti-TNF therapy has been shown to reduce the
progression of radiographic joint damage signifi-
cantly in RA patients.9–11 A few studies have also
suggested that anti-TNF therapy may prevent
general bone loss.12–14
Quantitative hand bone measures have been
recommended for their sensitivity to assess inflam-
matory bone involvement in early RA.15 However,
only a few studies have examined the effect of anti-
inflammatory treatment (including anti-TNF ther-
apy) on hand bone loss in RA.4 14 16 17 Furthermore,
only one randomised controlled trial has been
conducted in which the anti-inflammatory effects
of prednisolone (7.5 mg daily) compared with
placebo were shown to reduce significantly not
only the rate of radiographic joint damage, but also
the rate of hand bone loss.17
The primary objective of this analysis was to
examine cortical hand bone loss in the three arms
of the PREMIER study: adalimumab plus metho-
trexate versus adalimumab monotherapy versus
methotrexate monotherapy and to evaluate asso-
ciations between hand bone loss and radiographic
progression. Our second objective was to identify
potential predictors of hand bone loss.
METHODS
Study sample and design
The radiographic and clinical data from this 2-year,
multicentre, double-blind, randomised controlled
study (PREMIER) have previously been described
in detail.11 In short, the efficacy and safety of
adalimumab plus methotrexate was compared
with adalimumab monotherapy and with metho-
trexate monotherapy in 799 adult patients with
early (,3 years, mean disease duration
9.1 months), aggressive RA (inclusion criteria: >8
swollen joints; erythrocyte sedimentation rate >28
or C-reactive protein (CRP) >1.5 mg/dl; erosions
or rheumatoid factor positive), who previously had
not been treated with methotrexate, cyclopho-
sphamide, cyclosporine, azathioprine or more than
two other disease-modifying antirheumatic drugs
(DMARD) (table 1).11 The combination group
received adalimumab 40 mg subcutaneously every
other week plus weekly methotrexate by mouth
(rapidly increased to 20 mg/week), and the mono-
therapy groups received either adalimumab 40 mg
subcutaneously every other week plus placebo or
weekly methotrexate by mouth plus placebo.
Radiographs from hands and feet were scored
according to the modified Sharp score (range 0–
398).11
From this study, we present hand bone loss data
at 26, 52 and 104 weeks of follow-up. To maintain
the original study design of a blinded randomised
controlled trial, the treatment code was kept secret
for one of the authors who analysed the data
(MH).
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DXR hand bone measure
Digital x ray radiogrammetry (DXR; Sectra, Linko¨ping, Sweden)
was used to measure hand bone mineral density (BMD) and the
metacarpal cortical index (MCI) on the same digitised hand x
rays used for the assessment of radiographic joint damage. DXR
is a computer version of the traditional radiogrammetry
technique18 and the method has previously been described in
detail.19–21 On hand radiographs, the computer automatically
recognises regions of interest around the narrowest part of the
second, third and fourth metacarpal bone and measures cortical
thickness, bone width and porosity 118 times per centimetre.
DXR–BMD is defined as: c6VPAcomb6 (1 2 p), where c is a
density constant, VPA is volume per area and p is porosity.
DXR–MCI is defined as the combined cortical thickness divided
by the bone width and is a relative bone measure independent
of bone size and bone length.21 22 In the literature short-time in-
vivo precision (CV%) has been reported to range from 0.28% to
0.59% for DXR–BMD and from 0.31% to 0.64% for DXR–
MCI.19 21 23
DXR–BMD was intended to be the main outcome measure in
this study. However, many radiographs could not be analysed
for BMD because of unknown image resolution. The equation
for DXR–BMD is based on volume per area and requires a
known resolution, because a distance in a digitised radiograph
cannot be measured when the resolution is unknown.
Therefore, DXR–MCI, which is a relative measure less
dependent on image resolution, was used as the primary
outcome measure. The correlation between DXR–BMD and
DXR–MCI has been shown to be substantial (r . 0.90), both
cross-sectionally24 and longitudinally.25
For comparison, we also present results for DXR–BMD. All
images with unknown resolution were analysed by assuming
254 dpi (the scanning resolution for the radiographs before
scoring). Several of the radiographs were, however, clearly of a
resolution other than 254 dpi, most likely because these
radiographs had been printed in non-true size before scanning.
We analysed all available images for DXR–BMD at baseline, as
well as 26, 52 and 104 weeks and calculated DXR width. Based
on analyses from studies with a controlled resolution,25 a
deviation from baseline width greater than 2% was likely to
indicate an incorrect value. By using this 2% value as a cut-off,
23% of the radiographs were excluded from further DXR–BMD
analyses. The flow chart in fig 1 illustrates the patients who
were included in the DXR–MCI and DXR–BMD analyses.
To avoid bias regarding dominant and non-dominant hand
and to achieve better precision, we employed mean value
measurements from both hands.15 If the radiograph from one
hand could not be analysed, we used the radiograph from the
available hand for all analyses at all time points.
The radiographs were acquired by a single emulsion
mammography film; film focus distance 100 cm; tube voltage
50–55 kV according to the radiographic equipment and the
exposure dose was 8 mAs.
Statistical analysis
As the data were skewed, non-parametric analyses were
conducted. No imputations were performed. Baseline values
were compared between treatment groups with the Kruskall–
Wallis method for continuous variables and the x2 method for
categorical variables. Comparisons of changes in DXR were
conducted using methodologies employed in the original
PREMIER study.11 Two groups were compared in a hierarchical
order with the Mann–Whitney U test, ie, two-sided comparison
of the combination group versus methotrexate, followed by
two-sided comparisons between the adalimumab monotherapy
and methotrexate monotherapy treatment arms and finally
two-sided comparisons between the adalimumab monotherapy
and the combination group. Each pair-wise comparison was
completed only if the previous comparison was statistically
significant. Bone loss over time was expressed as a negative
value.
A linear regression model was developed to search for
predictors of hand BMD loss at 26, 52 and 104 weeks.
Table 1 Baseline characteristics for early RA patients in PREMIER*
Adalimumab +
methotrexate
(N = 261)
Adalimumab
monotherapy
(N = 261)
Methotrexate
monotherapy
(N = 246)
Demographic characteristics
Age, years 52.2 (13.8) 51.9 (13.7) 51.9 (13.3)
Female, no (%) 187 (71.6) 205 (78.5) 181 (73.6)
Clinical characteristics
Disease duration, years 0.7 (0.8) 0.7 (0.8) 0.8 (0.9)
Previously taken DMARD, no (%) 84 (32.2) 87 (33.3) 78 (31.7)
Previously taken corticosteroids, no (%) 92 (35.2) 94 (36.0) 85 (34.6)
Tender joint count, 0–66 31.1 (14.1) 31.7 (13.5) 32.2 (14.3)
Swollen joint count, 0–66 21.2 (11.1) 21.7 (10.2) 21.6 (11.3)
C-reactive protein, mg/l 39.5 (42.4) 40.7 (38.6) 40.6 (41.2)
HAQ, 0–3 1.5 (0.6) 1.6 (0.6){ 1.5 (0.7)
DAS28 6.3 (0.9) 6.4 (0.9) 6.3 (0.9)
Image analysis
Modified TSS
Mean 18.1 (20.3) 18.4 (18.2) 21.5 (21.8)
Median (25–75th percentile) 12.8 (6.0–24.0) 13.5 (5.1–25.5) 15.5 (7.5–28.5)
DXR–MCI 0.45 (0.09) 0.45 (0.09) 0.46 (0.08)
DXR–BMD, g/cm2 0.57 (0.08) 0.57 (0.08) 0.58 (0.08)
*Except where indicated results are given in mean (standard deviation) for continuous variables and numbers and percentages for
categorical variables. {Significantly higher values in the adalimumab group compared with both the methotrexate and the
combination group. BMD, bone mineral density; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic
drugs; DXR, digital x ray radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical index; RA, rheumatoid
arthritis; TSS, total Sharp score.
Extended report
1172 Ann Rheum Dis 2009;68:1171–1176. doi:10.1136/ard.2008.091264
Spearman correlation analyses were conducted in an attempt to
correlate changes in DXR–MCI with the following baseline
variables: disease duration; disease activity measured by 28-joint
disease activity score (DAS28);26 CRP; disability index of health
assessment questionnaire (HAQ) scores;27 previous use of
DMARD and cortisone; radiographic joint damage; randomised
treatment arm and absolute DXR–MCI value. The variables
with a p value less than 0.15 were included in the multivariate
model, which was also adjusted for age and gender. Treatment
arm was coded as a dummy variable (methotrexate as 0,
adalimumab as 1 and combination group as 2).
The PREMIER study was approved by a central institutional
review board and independent ethics committees at each
participating site.11
RESULTS
Baseline DXR–MCI values were available for 768 of the 799
patients enrolled in the PREMIER study and DXR–MCI values
were missing for two of 539 patients who completed the study
(fig 1). The corresponding numbers for available DXR–BMD
data (based on the cut-off values for image resolution described
in the Methods section) were 765 and 369, respectively (fig 1).
Demographics and baseline clinical characteristics for the whole
group were comparable between the three treatment arms
(table 1).
The only statistically significant difference between treat-
ment arms was a slightly greater mean HAQ score for the
adalimumab monotherapy group. Before enrollment, corticos-
teroids had been used in 35% of the patients (mean daily dosage
of prednisolone was 6.6 mg) and 32% had been treated with
traditional DMARD other than methotrexate. The baseline
radiographic damage scores were similar across treatment
groups, with a median (mean) Sharp score of 14.0 (19.3)
(table 1).
Median percentage DXR–MCI changes for all patients were
21.29, 22.45 and 23.72 at 26, 52 and 104 weeks.
Corresponding values for DXR–BMD were 21.07%, 21.72%
and 22.63%. Changes from baseline in DXR–MCI and DXR–
BMD were significant for all subgroups at all time points during
follow-up (p,0.001 for all). The use of corticosteroids or
DMARD did not affect hand bone loss (data not shown).
Correlation coefficients (r) between the DXR–MCI and the
DXR–BMD changes were 0.88, 0.93 and 0.94 at 26, 52 and
104 weeks (p,0.001 for all).
DXR–MCI changes between treatment arms
At 26, 52 and 104 weeks follow-up median percentage DXR–
MCI changes were 21.15, 22.16 and 23.03 for the adalimumab
plus methotrexate combination group, 21.33, 22.45 and 24.03
for the adalimumab monotherapy group and 21.42, 22.87 and
24.62 for the methotrexate monotherapy group (fig 2).
The rate of DXR–MCI loss was significantly greater for the
methotrexate group compared with the combination group at
Figure 1 Flow chart of the examined patients with early rheumatoid
arthritis in the present analysis. Numbers of missing x rays compared
with the original PREMIER study are provided in parentheses. BMD, bone
mineral density; DXR, digital x ray radiogrammetry; MCI, metacarpal
cortical index; MTX, methotrexate.
Figure 2 Changes in DXR–MCI (percentage) and modified Sharp score
(units) over time in the three treatment groups of PREMIER (A, median
values; B, mean values). DXR, digital x ray radiogrammetry; MCI,
metacarpal cortical index; Mod Sharp, modified total Sharp score; MTX,
methotrexate.
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52 weeks (p=0.009) and 104 weeks (p,0.001) and the same
trend was also observed at 26 weeks (p=0.19). DXR–MCI
reduction in the adalimumab monotherapy group was numeri-
cally lower than in the methotrexate group at 104 weeks
(p=0.10).
DXR–BMD changes between treatment arms
The median DXR–BMD percentage changes at 26, 52 and
104 weeks were, respectively, 21.06, 21.63 and 22.49 in the
combination group, 20.96, 21.97 and 22.40 for the adalimu-
mab group and 21.20, 21.86 and 23.58 for the methotrexate
group. The median DXR–BMD loss in the adalimumab group
was numerically slightly less than in the combination group
both at 26 and 104 weeks. However, the mean loss in the
adalimumab group was greater at all time points (see
supplementary table available online only). A significant
difference between the DXR–BMD change in the methotrexate
group and the combination group at 104 weeks (p=0.049) was
observed and a trend at 52 weeks (p=0.10). A trend towards a
difference between the methotrexate and adalimumab groups
was observed at 104 weeks (p=0.16).
Analyses on DXR–cortical thickness (DXR–CT) and DXR–
bone width (DXR–W) were also performed on the same
subgroups that were analysed for DXR–BMD. DXR–CT
showed the same pattern of bone loss as DXR–BMD and
DXR–MCI. DXR–W was stable at all time points and was not
influenced by treatment (see supplementary table available
online only).
DXR–MCI and radiographic damage
The median (mean) radiographic changes in modified Sharp
score at 26, 52 and 104 weeks, respectively, were 0 (0.5), 0 (0.9)
and 0 (1.0) for the combination group, 0.5 (2.1), 0.5 (3.3) and 1.0
(4.8) for the adalimumab monotherapy group and1.0 (3.4), 2.0
(5.1) and 2.0 (6.4) for the methotrexate monotherapy group
(fig 2). The discrepancy in the results of this analysis compared
with findings of the original PREMIER study is probably a result
of the slight differences in the number of study participants
(fig 1) and the fact that no imputations were conducted in the
present study. The correlations (r) between DXR–MCI change
and change in Sharp score at 26, 52 and 104 weeks were
r = 20.12 (p=0.001), r = 20.23 (p,0.001) and r = 20.32
(p,0.001). Comparable r values for correlations between DXR–
BMD and Sharp score changes were 20.15, 20.23 and 20.33,
respectively (p,0.001 for all).
Multivariate model
At all time points the variables included in the final multivariate
model were baseline values of disease duration, DAS28 score,
CRP, DXR–MCI, HAQ, radiographic damage and treatment
group (dummy variable), together with age and gender.
At 52 and 104 weeks, older age, greater CRP and non-use of
adalimumab turned out to be independent predictors for
cortical hand bone loss. At 26 weeks, female gender and greater
CRP were predictors of cortical hand bone loss. The model for
104 weeks is depicted in table 2.
DISCUSSION
The key finding of this analysis was that anti-TNF therapy with
adalimumab in combination with methotrexate provided better
bone protection than either adalimumab or methotrexate
monotherapies in patients with early, aggressive RA. The order
of hand bone loss across the three treatment arms was the same
as has been observed for overall radiographic damage in the
PREMIER study (fig 2). Furthermore, the results from the
multivariate model highlight the importance of inflammation
(assessed with CRP) as the driving force for bone damage in
active RA and the importance of TNF involvement in this
process.
The present analysis adds evidence to the hypothesis that
both erosions and osteoporosis are a result of the same
pathophysiological mechanism, which includes activation of
the osteoclast cell. This hypothesis is based on findings from
both animal6 28 and human7 studies.
Table 2 Predictors for percentage DXR–MCI loss at 104 weeks follow-
up in 515 RA patients explored by a multivariate linear regression model
DXR–MCI percentage change at 104 weeks
Beta p Value
Age, years 20.25 ,0.001
Female gender 20.04 0.36
Disease duration, years 0.06 0.11
C-reactive protein, mg/l 20.23 ,0.001
DAS28 20.09 0.07
Treatment group* 0.16 ,0.001
R2, adjusted 0.19
*Treatment groups coded as a dummy variable: 0, methotrexate; 1, adalimumab; 2,
adalimumab plus methotrexate. MCI baseline, Sharp score baseline and HAQ did not
influence the model. DAS28, 28-joint disease activity score; DXR, digital x ray
radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical
index; RA, rheumatoid arthritis.
Figure 3 Cumulative probability plot: changes in DXR–MCI and
radiographic scores at 104 weeks in PREMIER. DXR, digital x ray
radiogrammetry; MCI, metacarpal cortical index; mod Sharp score,
modified total Sharp score; MTX, methotrexate.
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Convincing data exist that the suppression of inflammation is
important to avoid bone damage in RA. Anti-TNF therapy has
in several clinical trials been shown to reduce the progression of
joint erosion.9–11 Furthermore, there is also evidence that anti-
TNF therapy reduces osteoporosis at the hip and spine.4 12–14
The ability of anti-inflammatory treatment to reduce hand
bone loss in RA has been demonstrated in a double-blind study
comparing oral prednisolone 7.5 mg/day for 2 years with
placebo. The prednisolone group had less hand BMD loss at 1
and 2 years, suggesting that the potent anti-inflammatory
effect of prednisolone exceeded its negative effect on bone.17
With respect to the effects of anti-TNF therapy on hand bone
loss in RA, only a few studies have been conducted. RA patients
treated with anti-TNF therapy have been shown to have a
lower rate of bone loss at the spine and hip than at the hand.4 14
In a 2-year longitudinal treatment strategy study (the BeST
study), RA patients treated with anti-TNF therapy or high-dose
prednisolone were shown to have a lower rate of bone loss at
the hand than patients treated with conventional DMARD.4
Furthermore, in a study employing quantitative ultrasound, the
use of anti-TNF therapy had a positive effect on periarticular
bone.16 The beneficial effect of anti-TNF treatment on
inflammatory-related hand bone loss in RA is supported by
our observations.
Methotrexate has been reported to have negative effects on
bone and the term ‘‘methotrexate osteopathy’’ has been used to
describe a clinical syndrome characterised by stress fractures,
diffuse bone pain and osteoporosis in children treated for
malignancies.29 In animal studies high-dose methotrexate has
been shown to induce apoptosis and suppress proliferation of
the growth plate chondrocytes as well as proliferation of the
osteoblasts and preosteoblasts.30 However, low-dose methotrex-
ate (5–20 mg/week) both in cross-sectional31 32 and longitudi-
nal33 studies has not shown any negative effect of methotrexate
on bone.
Despite the fact that bone loss was considerably lower in the
combination group than in the methotrexate group, these
patients were still losing hand bone. This loss may have been a
result of the substantial disease activity in the PREMIER RA
patients and their poor prognosis in terms of bone damage
(rheumatoid factor-positive and erosive disease).34
The positive effects of anti-TNF therapy seemed to be more
pronounced for radiographic joint damage than for hand bone
mass (fig 2). One explanation for this may be that conventional
radiographs are not sensitive enough to detect bone damage.
Both ultrasound and magnetic resonance imaging (MRI) have
been demonstrated to be more sensitive than radiographs in
detecting erosions.35 Furthermore, MRI can detect erosions years
before they become visible on radiographs36 and MRI synovitis
has been detected in RA patients in both clinical and radio-
graphic remission.37 Although MRI and ultrasound are sensitive
to detect erosions, there are still some limitations for clinical use
due to availability and the lack of validated scoring systems.
Hand bone loss assessed by dual x ray absorptiometry has also
been shown to be a more sensitive marker for bone damage than
conventional radiographs.15 Therefore, the combination of ever-
present inflammation in patients with greater disease activity,
as well as the ability of DXR to detect small changes in bone
mass, may explain the ongoing loss of hand bone. It is also
important to note the influence of normal age-related bone loss
that takes place in healthy adults, especially postmenopausal
women. Normal bone loss for DXR–MCI has only been
examined in cross-sectional studies reporting an annual rate of
bone loss between 0.7% and 0.9%.21 38 39
When this analysis was planned, we intended to analyse
radiographs primarily for DXR–BMD, but for reasons described
in the Methods section, there were difficulties in analysing a
large percentage of the radiographs for DXR–BMD. By using the
relative DXR–MCI measure instead of the absolute measure of
BMD, we lost the opportunity to correct for porosity.
Furthermore, DXR–BMD, as opposed to DXR–MCI, is cali-
brated for blurring and particular qualities of the different
radiographic measurement equipment. However, DXR has
improved the precision of MCI22 and there is a strong correlation
between DXR–BMD and DXR–MCI (r . 0.9).24 25 DXR–MCI
and DXR–BMD have also been found to be greatly correlated
with dual x ray absorptiometry–BMD.25 On the basis of these
facts, we believe DXR–MCI to be a valid surrogate measure of
hand bone mass.
Another limitation was our inability to retrieve information
on the use of bisphosphonates. This may be of importance as
treatment with bisphosphonates increases bone density. For the
potent bisphosphonate, zoledronic acid, the suppression of
osteoclast activity has even been shown to reduce the
progression of erosions both in animal40 and human7 studies.
Anti-TNF therapy inhibits the osteoclast by suppressing
inflammation and decreases the RANK/RANKL pathway, while
the aminobisphosphonate zoledronic acid acts directly on
osteoclasts. However, we believe that the study design of a
double-blind, randomised controlled trial has minimised the
effect of this potential bias. In addition, zoledronic acid was not
on the market for osteoporosis treatment when the PREMIER
study was conducted. Furthermore, in an observational study
the positive effect of infliximab on bone was found to be
independent of bisphosphonate use.12
In conclusion, our analysis of data from PREMIER provides
evidence that potent anti-TNF therapy not only reduces the risk
of developing erosions, but also reduces the rate of inflamma-
tory-related hand bone loss in RA. This study also suggests that
the bone damage disease process is still present in RA patients
treated with TNF antagonists, even if radiographic joint damage
on radiographs is apparently arrested. Based on the findings
from the present and previous studies, quantitative measures of
hand bone loss in RA patients can be recommended as outcomes
for future clinical trials to detect ongoing bone damage.
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Abstract
Digital X-ray radiogrammetry (DXR) calculates peripheral bone mineral density (BMD) from hand radiographs.
The aim of this study was to examine in vitro and in vivo precision for the new direct digital version of DXR, a de-
velopment of the conventional DXR. The in vitro precision for direct DXR was tested on 4 different X-ray equip-
ments, based on 31 radiographs of the same phantom. The in vivo precision was based on duplicate hand radiographs
from both hands in 39 individuals. For the 4 X-ray equipments, in vitro precision ranged from 0.14% to 0.30%, ex-
pressed as coefﬁcient of variations (CV%) and from 0.0012 to 0.0028 g/cm2, expressed as smallest detectable dif-
ference (SDD). The precision was correlated to the resolution of the radiographic equipment (r5 0.95, p5 0.05).
The corresponding values for the in vivo precision for mean values of both hands were: CV%5 0.46%;
SDD5 0.0046 g/cm2, and least signiﬁcant change (LSC%)5 1.28%. The DXR-BMD for 1 of the X-ray equipments
differed 1.1% from the overall mean. The precision for direct DXR was highly satisfactory both in vitro and in vivo.
DXR-BMD values may differ between the radiographic equipments, and follow-up measurements should be
performed with the same X-ray equipment.
Key Words: Digital X-ray radiogrammetry; Hand bone mineral density; Periarticular osteoporosis; Precision;
Rheumatoid arthritis.
Introduction
Dual-energy X-ray absorptiometry (DXA) measurements
at hip and spine are considered the gold standard for detection
and management of osteoporosis (1e3). Because DXA is
considered as a resource-demanding method, there is a need
for less expensive and more feasible methods to measure
bone mineral density (BMD). In the past decade, several
peripheral BMD measurements have been developed (4), in-
cluding digital X-ray radiogrammetry (DXR) (5). DXR calcu-
lating BMD at metacarpal hand bones on radiographs is
a further development of the classic radiogrammetry method
ﬁrst described in 1960 (6). DXR-BMD has been shown to be
a good predictor of fractures (7) and radiographic joint dam-
age in rheumatoid arthritis (RA) (8,9), and is also a response
variable for anti-inﬂammatory treatment (10,11).
For the DXR equipment that assesses bone density from
scanned conventional hand radiographs (Pronosco X-posure,
Sectra, LinKo¨ping, Sweden), the short-time precision is
shown to be superior compared with DXA assessed at hand,
hip, and spine (12,13). The DXR method has been further de-
veloped, and DXR-BMD can now also be analyzed directly
from digital hand radiographs (direct DXR).
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The precision for direct DXR has not been fully investi-
gated, and the objective of this study was to examine both in
vitro and in vivo reproducibility for the direct version of DXR.
Methods
Direct DXR (Sectra, Linko¨ping, Sweden), a further devel-
opment of the DXR method developed for BMD calculations
on conventional hand radiographs, was used to measure hand
BMD on radiographs made in digitized format. DXR is a com-
puter version of the traditional radiogrammetry technique (6),
and has been described in detail (5,14). The computer auto-
matically recognizes regions of interest around the narrowest
part of the second, third, and fourth metacarpal bone on hand
radiographs and measure cortical thickness, bone width, and
porosity 118 times per cm. DXR-BMD is deﬁned as:
cVPAcomb (1e p), where c is a density constant, VPA
is volume per area, and p is porosity.
In the in vitro study, hand DXR-BMD was measured on the
same cadaver forearm phantom 31 times with repositioning of
the phantom between each radiograph, tested on four different
standard X-ray equipments. All digitized radiographs were
sent to Sectra and analyzed with the same software. The four
X-ray equipments (computed radiography (CR)/digital radiog-
raphy (DR); ﬁlm focus distance (FFD); tube voltage; exposure
dose)were: Fuji FCRXG1 (FujiﬁlmCorporation,Tokyo; Japan)
(CR; 100 cm; 50 kV; 5mAs), Fuji FCR Profect (Fujiﬁlm Corpo-
ration, Tokyo; Japan) (CR; 100 cm, 40 kV; 8mAs), Agfa ADC
Compact plus (Afga-Gevaert N.V., Mortsel, Belgium)(CR;
100 cm; 50 kV; 5mAs) and Sectra MicroDose D40 (Sectra,
Linko¨ping, Sweden)(DR; built-in; 35kV; 10mAs) (Table 1).
The participants for the in vivo precision study were re-
cruited from consecutive individuals visiting an osteoporosis
outpatient clinic, and were selected according to their BMD
total hip values, 20 with osteoporosis and 20 with normal
values. Unfortunately, 1 radiograph could not be analyzed
for DXR-BMD. Thus, 19 individuals with osteoporosis and
20 with normal DXA-BMD values were included. All partic-
ipants underwent duplicate hand radiographs with reposition
between each image. The radiographs were acquired with
Fuji FCR XG1 (CR; FFD5 100 cm; tube voltage5 50 kV;
exposure dose5 5 mA).
The study was based on the current International Society
for Clinical Densitometry recommendation doing precision
analyses with at least 30 degrees of freedom (13) (http://
www.iscd.org).
Statistics
Regarding the in vitro study, differences between precision
for the four digitized equipments were calculated according to
Levene’s test for variances. Bonferroni approach was used to
adjust for multiple comparisons. Standard deviation (SD) was
calculated as SD5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPnj
i51ðxijexÞ2=nje1
q
(15), and coefﬁ-
cient of variation (CV%) was deﬁned as (SD/mean) 100.
The measurement error was calculated using Bland Altman
95% limits of agreement method (16). This gives an absolute
and metric estimate of random measurement error, also called
smallest detectable difference (SDD). Most disagreements be-
tween measurements are expected to be between limits called
‘‘limits of agreements,’’ deﬁned as: d z(1ea/2) SD, where
d is the mean difference between the measurements and
z(1ea/2) is the 100(1ea/2)th centile of the normal distribution.
The mean difference (d ) is expected to be 0, because we do
not assume a true change in BMD to occur between the mea-
surements (16,17).
In the in vivo study with 2 observations for each subject, the
SD of the difference ðSDdiffÞ5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðPðaiebiÞ2Þ
q
=2n estimated
the within variability of the measurements. This gives
aCV%5ð
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ððPðaiebiÞ2Þ=2nÞ
q
Þ=ððMaþMbÞ=2Þ  100 (where
ai and bi are the 2measures from the same individual [i],Ma and
Mb are mean values of a and b, and n is the number of paired
observations) (15,17). SDD was calculated in the same way
as in the in vitro study, but SDdiff was used instead of SD
(SDD5 d z(1ea/2) SDdiff) (15). The least signiﬁcant
change (LSC%), the percentage change in BMD in an individ-
ual, which is considered to be statistically signiﬁcant, was also
calculated (LSC%5 z(1ea/2) O2 CV%) (15,18).
Statistical analyses were performed with SPSS version 14
(SPSS inc., Chicago, IL) and Excel (Microsoft Ofﬁce, Micro-
soft Corporation).
Table 1
Precision Data for the In Vitro Digital Radiographs for DXR-BMD Tested in 4 Different X-ray Equipments
X-ray equipment center Resolution (mm/pixel)
Mean BMD
value (g/cm2) Variance CV% SDD (g/cm2)
Fuji FCR XG1, Kristiansand 0.100 0.471 1.0E-06 0.22 0.0020
Agfa ADC Compact plus, Trondheim 0.114 0.472 2.1E-06b 0.30 0.0028
Fuji FCR Profect, Helsingborg 0.050 0.472 6.1E-07 0.16 0.0015
Sectra MicroDose, Helsingborg 0.049 0.465a 3.9E-07 0.14 0.0012
Abbr: DXR, digital X-ray radiogrammetry; BMD, bone mineral density; CV%, coefﬁcient of variation; SDD, smallest detectable differ-
ence.
aDiffer by 1.1% from the overall mean.
bFuji FCR Profect and Sectra MicroDose had a signiﬁcantly better variance than the Agfa ADC Compact plus equipment.
18 Hoff et al.
Journal of Clinical Densitometry: Assessment of Skeletal Health Volume 12, 2009
Ethics and Legal Aspects
The in vivo study was approved by the regional committee
for ethics and medical research.
Results
In Vitro
The in vitro precision data (variance, CV%, and SDD) for
the 4 X-ray equipments are shown in Table 1. The DXR-BMD
mean for all measurements was 0.470 mg/cm2. The DXR-
BMD mean for the most diverging X-ray equipment, the Sec-
tra MicroDose, differed 1.1% from this overall mean (Table 1
and Fig. 1).
The precision for the 4 X-ray equipments tested ranged
from 0.14% to 0.30% for CV% and from 0.0012 to
0.0028 g/cm2 for SDD (Table 1). The resolution and the preci-
sion of the equipment correlated signiﬁcantly (r5 0.95,
p5 0.05), that is, high resolution resulted in high precision.
Fuji FCR Profect and Sectra MicroDose had a signiﬁcantly
better variance than the Agfa ADC Compact plus ( p! 0.001).
In Vivo
The in vivo precision results for direct DXR-BMD are
displayed in Table 2. A Bland Altman plot for direct DXR
is depicted in Fig. 2. The CV% for DXR-BMD was 0.61
for the nondominant hand, and improved to 0.46 using
mean DXR-BMD of both hands. The mean DXR-BMD for
the osteoporotic group was 0.435 mg/cm2, whereas the
mean DXR-BMD for the individuals with no osteoporosis
was 0.596 mg/cm2. There was no signiﬁcant difference for
the CV% between these 2 groups (0.45% for both; p5 0.36
between variances).
Discussion
The short-time precision, both in vitro and in vivo, for
direct DXR-BMD was highly satisfactory. The utility of
DXR-BMD in research and clinical practice has been demon-
strated in several studies (7,8,19,20), and our observation sup-
ports the fact that DXR-BMD is a robust measure.
The in vitro precision for the 4 tested X-ray equipments
expressed as CV% ranged from 0.14% to 0.30%. The repro-
ducibility was dependent on the resolution capacity of the
tested X-ray equipments as shown in Table 1.
The in vivo precision for direct DXR-BMD was compara-
ble to that reported for scanned DXR-BMD (CV%:
0.28e0.68%) (5,14,21). The new direct DXR is more feasible
to use than scanned DXR, as it does not require any manual
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Fig. 1. Cadaver phantom bone mineral density values and
variance in the 4 tested X-ray equipments (Box-and-whisker
plot: the marked line shows the median, the outer linings of
the box express the interquartile range, and the whiskers ex-
press the 95 percentage central range).
Table 2
Precision Data for the In Vivo Digital Radiographs
(Fuji FCR XG1)
Precision
Data
DXR-BMD (g/cm2)
Nondominant
hand
Mean of
both hands
Mean (SD) 0.506 (0.108) 0.510 (0.110)
SD difference 0.003 0.002
SDD, 95% limits
of agreement
0.0061 0.0046
CV% 0.61 0.46
LSC% 1.71 1.28
Abbr: DXR, digital X-ray radiogrammetry; BMD, bone mineral
density; SD, standard deviation; SDD, smallest detectable differ-
ence; CV%, coefﬁcient of variance; LSC%, least signiﬁcant change.
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Fig. 2. Graph of the difference score (g/cm2) against the
mean score (g/cm2) of the 2 digital X-ray radiogrammetry-
bone mineral density measurements in the in vivo study
(Bland Altman plot). The dashed lines represent the 95%
limits of agreement.
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scanning of the radiographs. The precision improved when
using mean values of both hands. In this study, the CV%
was reduced from 0.61% for BMD values of the nondominant
hand to 0.46% for the mean BMD values of both hands. Thus,
X-ray equipments with high resolution and mean BMD values
of both hands should be used to obtain the best precision for
DXR-BMD measurements. For use on the individual level,
a change of 1.28% (5LSC%) in DXR-BMD by the use of
mean BMD values of both hands is required to identify true
bone loss exceeding the measurement error.
It appeared that the precision in the in vitro study was bet-
ter than that in the in vivo study. One reason may be that the
phantom in the in vitro study is ﬁxed in one position, whereas
the human hands may vary in position. This may especially be
of importance in patients with RA, who might have defor-
mities or inﬂammation in their hands. Another reason may
be the difference in the number of images. Only 2 radiographs
were performed on humans because of the radiation exposure,
whereas there were 31 images of the phantom at each center.
The reproducibility for DXR was better than previous pre-
cision calculations for DXA measurements. The CV% for
DXA is reported to be 0.80e1.00% (or an LSC% of
2.22e2.77) at whole hand (22e24), 0.88e1.59% for total
hip, and 0.88e2.00% for lumbar spine (17,25,26). Further,
the precision for DXA is shown to be inﬂuenced by the
BMD in the examined patients, that is, low BMD values are
reported to have poorer precision than high BMD values
(25,26). Subanalysis in the present study suggests that this
is not the case with DXR-BMD, but further studies including
more patients are needed to clarify this (Fig. 2).
Another important observation was that the X-ray equip-
ments measured different values for the DXR-BMD. The Sec-
tra MicroDose differed 1.1% from the overall mean BMD
value (Fig. 1 and Table 1). The most likely explanation
may be the measurements of porosity. The X-ray equipment
that takes a sharply deﬁned picture may detect porosity better.
The BMD value will then be lower for high-porosity bones
and higher for low-porosity bones. This may explain why
the Sectra MicroDose, which is a high-resolution mammogra-
phy system, measured a different BMD value than the other
equipments. Other reasons for the differences in BMD may
be different spectra of the X-rays or blurring of the radio-
graphs. These observations support the fact that the same
X-ray equipment should be used for longitudinal follow up
of individuals. Regarding the analyses of conventional X-
rays, the precision does not seem to be inﬂuenced either by
ﬁlm brand, FFD, or exposure level, but tube voltage may
have an inﬂuence (27,28). To our knowledge, there is a lack
of data on long-term reproducibility for both scanned and di-
rect DXR.
The ability of DXR to detect even small changes in BMD
makes the method suitable for assessment at the individual
level. In a study of osteoporotic women, annual DXR-BMD
loss was found to be 0.004 g/cm2 or 0.8% (29). In RA patients,
the annual loss of DXR-BMD has been shown to range from
1.7% (or an absolute median value of 0.009 g/cm2) (8) to as
much as a mean loss of 10% in patients with a high disease
activity (19). This means that the DXRmethod has the capacity
to capture a signiﬁcant DXR-BMD change over a short period
of time. When combining these results with the LSC% of
1.28%, a signiﬁcant DXR-BMD loss can be detected at
1.5 months in RA patients with high disease activity (monitor-
ing time interval5 LSC%/annual percentage loss) (30). Early
loss of DXR-BMD in RA patients is shown to predict subse-
quent radiographic damage, and a rapid loss of hand DXR-
BMDmay, therefore, be a candidate predictor for poor progno-
sis (8,9).
A limitation of this study is that different methods were
used in the in vitro and in vivo part of the study. However,
to expose patients with radiation with the same number of
X-rays as we did with the phantom were considered as uneth-
ical. Another limitation for the in vivo precision study was
that no patients with RA were included.
In conclusion, the direct DXR method had highly satisfac-
tory precision, and may, thus, be a potential important re-
search and clinical tool for short-time follow-up of both
osteoporotic and RA patients. Concerning the RA patients,
it is an advantage that DXR-BMD can be analyzed on the
same radiographs used for follow-up destruction, making
the method feasible. It is important that follow-up radiographs
are taken with the same X-ray equipment. Long-time preci-
sion studies are warranted to further validate the method.
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